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1. Introduction: Dengue virus  









































































































































































































































































































































































































































































































































































































































































2.2.3 Metabolic Labeling of DENV-infected and mock-
infected mammalian cells 
Metabolic labeling of actively translated proteins during DENV‐ and mock‐
infection was performed in two mammalian cell types: HuH7 and U937+DC‐SIGN.  




















































2.2.4 Expression of GFP-fusion proteins 






Each  15  centimeter  plate  of  confluent  HEK293  cells  was  transfected  with  a 
mixture of 30 μg of GFP‐NS5 DNA and 10 μL of transfection reagent (Xtreme Gene HP; 






2.2.5 Fluorescence-based small-molecule drug screen 
A  collection  of  10,000  compounds  was  initially  selected  from  commercially 
available compounds using previously described parameters (Fadden et al., 2010b). The 
collection of 10,000  compounds was analyzed by a group of medicinal  chemists, who 
eliminated  approximately  6,000  of  these  compounds  based  on  structural  liabilities 
including general reactivity with proteins side chains. A final total of 3,379 compounds 
were selected  for  the screen, and  individual compounds were purchased  from various 
commercial sources as described in Materials. The candidate compounds were prepared 




































































2.2.6 Flow cytometry-based assay to measure percent 


























































































































2.2.8 EC50 determination using cell-based flaviviral 

























































































































































3. Identification of purine-utilizing proteins 










































































3.1 Twenty-four hour time course in DENV-infected 








































































































































3.3 Comparison of the DENV purinomics profile with 


































vinculin  gi|31543942 Down  No  HepG2  (Pattanakitsakul 
et al., 2007) 
Succinate dehydrogenase, 




helicase DDX17  gi|3122595  Up  Yes  HepG2 
(Pattanakitsakul 
et al., 2007) 





gi|24660110 Down  Yes  HepG2  (Pattanakitsakul 
et al., 2007) 
Retinol dehydrogenase  gi|25141231 Up  Yes  HepG2  (Pattanakitsakul 
et al., 2007) 
ATPase, V0 subunit d1  gi|19913432 Up  Yes  HepG2  (Pattanakitsakul 
et al., 2007) 
Annexin 5  gi|4502107  Up  Yes  HepG2  (Pattanakitsakul 
et al., 2007) 
Dehydrogenase/reductase 





























































































































4. A fluorescence-based small-molecule screen 














4.1 Identification of lead compounds that disrupt the 






























































































































































































































































































































































5.2 Quantifying the titer of infectious DENV using a 































































































5.3 Independent viability assay to determine 






































5.4 Determination of EC50 for top 3 lead compounds in 










































































6. HS-205020 preferentially binds the RNA-
dependent RNA polymerase (RdRp) of DENV 























































































































































6.2 Determination of IC50 of HS-205020 against the 















































7. HS-205020 activity in a cell culture model of 

























7.3 HS-205020 reduces production of infectious virus 














































































































































































































































































































































































































































































































































Spot Idx/Pos 181/H17 1 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 CTCL tumor antigen se20-7 [Homo sapiens] gi|11385652 73769.5 56 98.434
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1302.7449 1302.7048 -0.0401 -31 125 135 VKQEVVDVMKK
1332.7191 1332.7322 0.0131 10 95 105 KLKAEMDEQIK
1635.8588 1635.8796 0.0208 13 74 88 AAFEELEKALSTAQK
1638.9788 1638.9512 -0.0276 -17 416 429 ALKDQINQLELLLK
1722.8591 1722.9172 0.0581 34 163 175 LQTREREFQEQMK
1764.8948 1764.9423 0.0475 27 167 180 EREFQEQMKVALEK
1765.9153 1765.9631 0.0478 27 294 307 LQVLKQQYQTEMEK
1767.9598 1767.9252 -0.0346 -20 136 150 SSEEQIAKLQKLHEK
1980.0647 1980.1284 0.0637 32 176 192 VALEKSQSEYLKISQEK
1980.0647 1980.1284 0.0637 32 176 192 VALEKSQSEYLKISQEK
2008.0344 2008.0818 0.0474 24 71 88 SERAAFEELEKALSTAQK
2011.0355 2011.0939 0.0584 29 434 450 HLKEHQAHVENLEADIK
2202.1111 2202.1943 0.0832 38 324 341 EIIFQAHIEEMNEKTLEK
2215.175 2215.208 0.033 15 16 34 NLIEQLEQDKGMVIAETK
R
2229.2271 2229.2144 -0.0127 -6 116 134 ISLQQELSRVKQEVVDVM
K
2373.2329 2373.291 0.0581 24 13 33 DAKNLIEQLEQDKGMVIA
ETK
2651.3523 2651.4546 0.1023 39 220 241 DLQQEAETYRTRILELES
SLEK
2783.4182 2783.4326 0.0144 5 393 415 NHHQQQVDSIIKEHEVSI
QRTEK
2783.4182 2783.4326 0.0144 5 393 415 NHHQQQVDSIIKEHEVSI
QRTEK
20 putative protein product of HMFN0672 [Homo sapiens] gi|51555 92622.3 40 28.403
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1108.6108 1108.6534 0.0426 38 59 67 RVLSNTYQK
1221.6698 1221.7092 0.0394 32 556 566 NGIYASRTLAR
1221.6698 1221.7092 0.0394 32 556 566 NGIYASRTLAR
1253.696 1253.7197 0.0237 19 172 181 LLHRTEELSR
1264.726 1264.7104 -0.0156 -12 444 453 EYIRKSLLDK
1288.7153 1288.7308 0.0155 12 386 395 NEMIKLQRTR
1298.6997 1298.7285 0.0288 22 756 765 EMEKLHRSLR
1334.7201 1334.7512 0.0311 23 494 504 FAEEKVELLEK
1735.9635 1735.9049 -0.0586 -34 551 566 AVCLKNGIYASRTLAR
1765.9199 1765.9631 0.0432 24 340 355 ACQRGFCRDVALVVTK
1875.9745 1875.9874 0.0129 7 312 328 CSVIWVISDIERVSGGR
2033.996 2034.0406 0.0446 22 746 762 ELADVGSEYKEMEKLHR
2227.2544 2227.2356 -0.0188 -8 225 244 IPTSRVITLKAEEAEELSIK
2240.2471 2240.2817 0.0346 15 348 366 DVALVVTKMDKLHLPEYL
R
2261.177 2261.1936 0.0166 7 235 253 AEEAEELSIKLDPYIRTQR
2299.1975 2299.1907 -0.0068 -3 706 724 AQERMQHQFQQLKTGIV
EK
2379.3394 2379.2786 -0.0608 -26 630 650 KNFLIQEISAILGGLEDHIL
R
2800.3423 2800.4329 0.0906 32 2 25 AETKDVFGQEPHPVEDD
LYKEPTR
28 dynamin 2 isoform 3 [Homo sapiens] gi|56549 97590.9 38 1.168
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
991.5683 991.6061 0.0378 38 446 453 LSSYPRLR
1106.5914 1106.6289 0.0375 34 559 567 YMLPLDNLK
1158.6729 1158.6517 -0.0212 -18 300 309 LQSQLLSLEK
1348.7471 1348.7173 -0.0298 -22 654 665 NLVDSYVAIINK
1474.776 1474.8234 0.0474 32 316 327 NFRPDDPTRKTK
1621.8835 1621.936 0.0525 32 400 414 TGLFTPDLAFEAIVK
1635.8448 1635.8796 0.0348 21 446 458 LSSYPRLREETER
1735.9125 1735.9049 -0.0076 -4 45 59 SSVLENFVGRDFLPR
1762.9445 1762.884 -0.0605 -34 230 245 GYIGVVNRSQKDIEGK
1875.9435 1875.9874 0.0439 23 257 271 KFFLSHPAYRHMADR
1899.9854 1899.9282 -0.0572 -30 669 684 DLMPKTIMHLMINNTK
2254.2666 2254.2515 -0.0151 -7 846 866 RPPAAPSRPTIIRPAEPSL
LD
2273.1692 2273.1973 0.0281 12 167 188 ESSLILAVTPANMDLANS
DALK
2289.2634 2289.1868 -0.0766 -33 654 673 NLVDSYVAIINKSIRDLMP
K
2341.1685 2341.2292 0.0607 26 365 382 IFHERFPFELVKMEFDEK
2497.2292 2497.2791 0.0499 20 570 590 DVEKGFMSNKHVFAIFNT
EQR
3139.824 3139.7295 -0.0945 -30 114 142 GISPVPINLRVYSPHVLNL
TLIDLPGITK
32 golgin-165 gi|55330 66309.7 38 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1074.6152 1074.6427 0.0275 26 415 423 EKEKVNSLK
1074.6152 1074.6427 0.0275 26 415 423 EKEKVNSLK
1081.5887 1081.6182 0.0295 27 341 349 LALELEHEK
1266.7052 1266.7295 0.0243 19 341 351 LALELEHEKGK
1266.7052 1266.7295 0.0243 19 341 351 LALELEHEKGK
1282.6862 1282.7196 0.0334 26 127 137 TAEAELSRLHR
1332.7117 1332.7322 0.0205 15 7 20 TGDSAALQAVKSGK
1348.733 1348.7173 -0.0157 -12 229 240 AYENAVGILSRR
1596.8162 1596.829 0.0128 8 113 125 ELRQELMQVHGEK
1635.8812 1635.8796 -0.0016 -1 5 20 FRTGDSAALQAVKSGK
1716.865 1716.8021 -0.0629 -37 312 325 EKVLELEDELQESR
1965.0624 1965.0811 0.0187 10 127 143 TAEAELSRLHREVAQVR
2014.0563 2014.1117 0.0554 28 530 546 EIQSLKQQLDLTEQQGR
2208.2234 2208.2935 0.0701 32 275 294 IQALEAELQAVSHSKTLL
EK
2208.2234 2208.2935 0.0701 32 275 294 IQALEAELQAVSHSKTLL
EK
2221.2773 2221.239 -0.0383 -17 376 394 READLVQLNLQVQAVLQ
RK
2299.2 2299.1907 -0.0093 -4 528 546 EREIQSLKQQLDLTEQQG
R
Spot Idx/Pos 182/H19 2 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 Splicing factor proline/glutamine-rich (polypyrimidine gi|29881667 76140.7 57 98.636
tract binding protein associated) [Homo sapi
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1120.5204 1120.5302 0.0098 9 682 693 GMGPGTPAGYGR
1143.6268 1143.6382 0.0114 10 366 376 FATHAAALSVR
1143.6268 1143.6382 0.0114 10 366 376 FATHAAALSVR
1153.6364 1153.6501 0.0137 12 333 342 GFGFIKLESR
1267.6211 1267.6398 0.0187 15 33 44 SPPPGMGLNQNR
1341.6656 1341.6849 0.0193 14 667 681 FGQGGAGPVGGQGPR
1341.6656 1341.6849 0.0193 14 667 681 FGQGGAGPVGGQGPR
1347.6776 1347.6803 0.0027 2 6 18 FRSRGGGGGGFHR
1398.7964 1398.801 0.0046 3 364 376 VRFATHAAALSVR
1649.8856 1649.9034 0.0178 11 272 286 ISDSEGFKANLSLLR
1743.8945 1743.8977 0.0032 2 343 358 ALAEIAKAELDDTPMR
1762.7819 1762.7941 0.0122 7 480 493 FAQHGTFEYEYSQR
1762.7819 1762.7941 0.0122 7 480 493 FAQHGTFEYEYSQR
1964.0123 1964.0171 0.0048 2 299 315 LFVGNLPADITEDEFKR
1964.0123 1964.0171 0.0048 2 299 315 LFVGNLPADITEDEFKR
2428.1196 2428.1335 0.0139 6 517 536 DKLESEMEDAYHEHQAN
LLR
2639.2986 2639.3003 0.0017 1 377 399 NLSPYVSNELLEEAFSQF
GPIER
2639.2986 2639.3003 0.0017 1 377 399 NLSPYVSNELLEEAFSQF
GPIER
2673.2791 2673.2612 -0.0179 -7 243 267 GGRQHHPPYHQQHHQG
PPPGGPGGR
4 tumor rejection antigen (gp96) 1 [Homo sapiens] gi|4507677 92411.3 44 73.399
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1015.473 1015.4883 0.0153 15 396 404 GLFDEYGSK
1485.7543 1485.766 0.0117 8 435 448 GVVDSDDLPLNVSR
1544.8278 1544.8228 -0.005 -3 103 116 ELISNASDALDKIR
1751.8243 1751.8429 0.0186 11 415 428 RVFITDDFHDMMPK
1751.8243 1751.8429 0.0186 11 415 428 RVFITDDFHDMMPK
2112.1116 2112.1108 -0.0008 0 143 161 NLLHVTDTGVGMTREEL
VK
2260.0627 2260.0723 0.0096 4 512 530 FQSSHHPTDITSLDQYVE
R
2260.0627 2260.0723 0.0096 4 512 530 FQSSHHPTDITSLDQYVE
R
2265.1145 2265.1028 -0.0117 -5 664 683 AQAYQTGKDISTNYYAS
QKK
2283.1414 2283.1443 0.0029 1 411 428 LYVRRVFITDDFHDMMPK
2299.0481 2299.0669 0.0188 8 640 660 LTESPCALVASQYGWSG
NMER
2728.3384 2728.3604 0.022 8 44 67 TDDEVVQREEEAIQLDGL
NASQIR
2733.4556 2733.4648 0.0092 3 701 724 IKEDEDDKTVLDLAVVLF
ETATLR
3157.5354 3157.5505 0.0151 5 40 67 EGSRTDDEVVQREEEAI
QLDGLNASQIR
Spot Idx/Pos 183/H21 3 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 premembrane [Dengue virus type 2] gi|18308050 13563.5 45 0 4 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1139.5625 1139.5715 0.009 8 7 16 NGEPHMIVSR 4 0
1139.5625 1139.5715 0.009 8 7 16 NGEPHMIVSR
1412.6151 1412.6093 -0.0058 -4 107 118 TETWMSSEGAWK
1524.7587 1524.7587 0 0 7 19 NGEPHMIVSRQEK
1565.8468 1565.8579 0.0111 7 92 106 SVALVPHVGMGLETR
1565.8468 1565.8579 0.0111 7 92 106 SVALVPHVGMGLETR
2 prM (M) protein [Dengue virus type 2] gi|25059129 18859.3 40 0 4 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1139.5625 1139.5715 0.009 8 7 16 NGEPHMIVSR 4 0
1139.5625 1139.5715 0.009 8 7 16 NGEPHMIVSR
1412.6151 1412.6093 -0.0058 -4 107 118 TETWMSSEGAWK
1524.7587 1524.7587 0 0 7 19 NGEPHMIVSRQEK
1565.8468 1565.8579 0.0111 7 92 106 SVALVPHVGMGLETR
1565.8468 1565.8579 0.0111 7 92 106 SVALVPHVGMGLETR
15 polyprotein [Dengue virus type 2] gi|582346 17119.3 33 0 4 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1139.5625 1139.5715 0.009 8 99 108 NGEPHMIVSR 4 0
1139.5625 1139.5715 0.009 8 99 108 NGEPHMIVSR
1524.7587 1524.7587 0 0 99 111 NGEPHMIVSRQEK
3337.7402 3337.7163 -0.0239 -7 79 108 TAGMIIMLIPTVMAFHLTT
RNGEPHMIVSR
16 polyprotein [Dengue virus type 2] gi|52219 17111.2 33 0 4 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1139.5625 1139.5715 0.009 8 99 108 NGEPHMIVSR 4 0
1139.5625 1139.5715 0.009 8 99 108 NGEPHMIVSR
1524.7587 1524.7587 0 0 99 111 NGEPHMIVSRQEK
3337.7402 3337.7163 -0.0239 -7 79 108 TVGMIIMLIPTAMAFHLTT
RNGEPHMIVSR
2 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 29 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1344.7633 1344.7715 0.0082 6 7 18 TFIAIKPDGVQR
1344.7633 1344.7715 0.0082 6 122 133 TFIAIKPDGVQR
1785.9163 1785.9147 -0.0016 -1 204 220 VMLGETNPADSKPGTIR
1785.9163 1785.9147 -0.0016 -1 89 105 VMLGETNPADSKPGTIR
Spot Idx/Pos 184/H23 4 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
4 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 23 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1344.7633 1344.7639 0.0006 0 122 133 TFIAIKPDGVQR
1344.7633 1344.7639 0.0006 0 7 18 TFIAIKPDGVQR
1785.9163 1785.9246 0.0083 5 89 105 VMLGETNPADSKPGTIR
1785.9163 1785.9246 0.0083 5 204 220 VMLGETNPADSKPGTIR
Spot Idx/Pos 193/H14 5 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 splicing factor homolog - human gi|543010 54233.3 65 99.794
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1147.6179 1147.6321 0.0142 12 271 279 WKALIEMEK
1195.6581 1195.6519 -0.0062 -5 110 119 GFGFIRLETR
1231.6792 1231.6819 0.0027 2 191 202 GIVEFSGKPAAR
1248.6735 1248.6707 -0.0028 -2 97 107 YGKAGEVFIHK
1457.7706 1457.7668 -0.0038 -3 338 348 KQLELRQEEER
1538.6694 1538.6843 0.0149 10 384 398 MGQMAMGGAMGINNR
1695.7471 1695.7589 0.0118 7 257 270 FAQPGSFEYEYAMR
1695.7471 1695.7589 0.0118 7 257 270 FAQPGSFEYEYAMR
1812.9888 1812.989 0.0002 0 120 135 TLAEIAKVELDNMPLR
1814.0031 1813.995 -0.0081 -4 185 202 GRPSGKGIVEFSGKPAA
R
1859.9207 1859.9332 0.0125 7 76 91 LFVGNLPPDITEEEMR
1859.9207 1859.9332 0.0125 7 76 91 LFVGNLPPDITEEEMR
1880.0183 1879.993 -0.0253 -13 138 153 QLRVRFACHSASLHVR
1988.0156 1988.0286 0.013 7 76 92 LFVGNLPPDITEEEMRK
2163.0649 2163.074 0.0091 4 435 456 FGQAATMEGIGAIGGTPP
AFNR
2163.0649 2163.074 0.0091 4 435 456 FGQAATMEGIGAIGGTPP
AFNR
2231.1487 2231.1167 -0.032 -14 74 92 SRLFVGNLPPDITEEEMR
K
2498.177 2498.1924 0.0154 6 294 313 EKLEMEMEAARHEHQVM
LMR
2668.3252 2668.3274 0.0022 1 154 176 NLPQYVSNELLEEAFSVF
GQVER
2668.3252 2668.3274 0.0022 1 154 176 NLPQYVSNELLEEAFSVF
GQVER
3451.7058 3451.7124 0.0066 2 399 434 GAMPPAPVPAGTPAPPG
PATMMPDGTLGLTPPTT
ER
12 polypyrimidine tract-binding protein 1 isoform c [Homo gi|14165466 57185.6 24 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1184.6521 1184.6644 0.0123 10 2 13 DGIVPDIAVGTK
1431.7379 1431.7369 -0.001 -1 123 134 GQPIYIQFSNHK
2039.0959 2039.0962 0.0003 0 349 366 VTPQSLFILFGVYGDVQR
2039.0959 2039.0962 0.0003 0 349 366 VTPQSLFILFGVYGDVQR
2144.0002 2144.0244 0.0242 11 419 437 EGQEDQGLTKDYGNSPL
HR
2275.2766 2275.2791 0.0025 1 326 348 IAIPGLAGAGNSVLLVSNL
NPER
2275.2766 2275.2791 0.0025 1 326 348 IAIPGLAGAGNSVLLVSNL
NPER
3206.5132 3206.5435 0.0303 9 95 122 NQAFIEMNTEEAANTMV
NYYTSVTPVLR
3391.6296 3391.6753 0.0457 13 93 122 GKNQAFIEMNTEEAANT
MVNYYTSVTPVLR
3680.8845 3680.8735 -0.011 -3 147 185 AQAALQAVNSVQSGNLA
LAASAAAVDAGMAMAGQ
SPVLR
Spot Idx/Pos 138/F4 6 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 non-POU domain containing, octamer-binding [Homo gi|34932414 54197.3 87 99.999
sapiens]
Protein Group
splicing factor homolog - human gi|543010 54233.3
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1147.6179 1147.5594 -0.0585 -51 271 279 WKALIEMEK
1180.5714 1180.5752 0.0038 3 305 313 HEHQVMLMR
1195.6581 1195.5901 -0.068 -57 110 119 GFGFIRLETR
1336.6235 1336.6051 -0.0184 -14 294 304 EKLEMEMEAAR
1480.7179 1480.6635 -0.0544 -37 366 378 QQEGFKGTFPDAR
1538.6694 1538.6031 -0.0663 -43 384 398 MGQMAMGGAMGINNR
1538.6694 1538.6031 -0.0663 -43 384 398 MGQMAMGGAMGINNR
1636.819 1636.7764 -0.0426 -26 365 378 RQQEGFKGTFPDAR
1695.7471 1695.6763 -0.0708 -42 257 270 FAQPGSFEYEYAMR
1695.7471 1695.6763 -0.0708 -42 257 270 FAQPGSFEYEYAMR
1812.9888 1812.8975 -0.0913 -50 120 135 TLAEIAKVELDNMPLR
1824.8479 1824.8483 0.0004 0 358 371 QQEEMMRRQQEGFK
1859.9207 1859.8271 -0.0936 -50 76 91 LFVGNLPPDITEEEMR
1859.9207 1859.8271 -0.0936 -50 76 91 LFVGNLPPDITEEEMR
2163.0649 2162.9634 -0.1015 -47 435 456 FGQAATMEGIGAIGGTPP
AFNR
2163.0649 2162.9634 -0.1015 -47 435 456 FGQAATMEGIGAIGGTPP
AFNR
2231.1487 2231.0532 -0.0955 -43 74 92 SRLFVGNLPPDITEEEMR
K
2303.0549 2303.0408 -0.0141 -6 252 270 EQPPRFAQPGSFEYEYA
MR
2498.177 2498.0669 -0.1101 -44 294 313 EKLEMEMEAARHEHQVM
LMR
2668.3252 2668.187 -0.1382 -52 154 176 NLPQYVSNELLEEAFSVF
GQVER
2668.3252 2668.187 -0.1382 -52 154 176 NLPQYVSNELLEEAFSVF
GQVER
3451.7058 3451.4951 -0.2107 -61 399 434 GAMPPAPVPAGTPAPPG
PATMMPDGTLGLTPPTT
ER
3 heterogeneous nuclear ribonucleoprotein M isoform b gi|14141154 73512.3 65 99.774
[Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1167.5833 1167.5872 0.0039 3 620 628 NLPFDFTWK
1214.5759 1214.6051 0.0292 24 38 48 GEGERPAQNEK
1336.671 1336.6051 -0.0659 -49 647 659 MENGKSKGCGVVK
1383.6143 1383.5405 -0.0738 -53 568 582 MGLAMGGGGGASFDR
1480.7069 1480.6635 -0.0434 -29 398 410 MGLVMDRMGSVER
1550.7413 1550.8208 0.0795 51 433 446 MGQTMERIGSGVER
1550.7413 1550.8208 0.0795 51 433 446 MGQTMERIGSGVER
1715.8164 1715.8145 -0.0019 -1 113 127 GCAVVEFKMEESMKK
1739.9591 1739.87 -0.0891 -51 70 83 RYRAFITNIPFDVK
1821.9163 1821.8356 -0.0807 -44 652 668 SKGCGVVKFESPEVAER
2163.0476 2162.9634 -0.0842 -39 589 612 GNFGGSFAGSFGGAGG
HAPGVARK
2163.0476 2162.9634 -0.0842 -39 589 612 GNFGGSFAGSFGGAGG
HAPGVARK
2211.05 2210.9856 -0.0644 -29 398 417 MGLVMDRMGSVERMGS
GIER
2249.0947 2248.9844 -0.1103 -49 512 531 MATGLERMGANNLERM
GLER
2273.1487 2273.0679 -0.0808 -36 465 485 VGQTIERMGSGVERMGP
AIER
2283.0896 2283.0515 -0.0381 -17 634 653 FNECGHVLYADIKMENG
KSK
2599.2107 2599.2087 -0.002 -1 365 390 MGPGIDRLGGAGMERM
GAGLGHGMDR
2733.3125 2733.1404 -0.1721 -63 493 518 MVPAGMGAGLERMGPV
MDRMATGLER
2829.416 2829.2468 -0.1692 -60 95 120 VGEVTYVELLMDAEGKS
RGCAVVEFK
12 ZNF225 [amino acids 79-706] [Homo sapiens] gi|9502402 73081.2 56 98.283
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1044.5221 1044.4824 -0.0397 -38 343 351 AHSGEKPYR
1380.6654 1380.621 -0.0444 -32 443 453 FTQNSQLYSHR
1403.6558 1403.5857 -0.0701 -50 268 278 CEECGKRFIYR
1550.7822 1550.8208 0.0386 25 415 426 FTQNSQLYTHRR
1550.7822 1550.8208 0.0386 25 414 425 RFTQNSQLYTHR
1566.7805 1566.735 -0.0455 -29 251 264 SALNSHRMVHTGEK
1695.765 1695.6763 -0.0887 -52 119 133 VHMGEKLYNCDVCGK
1695.765 1695.6763 -0.0887 -52 119 133 VHMGEKLYNCDVCGK
1715.8361 1715.8145 -0.0216 -13 338 351 YSHQRAHSGEKPYR
1729.8993 1729.8163 -0.083 -48 557 570 WASTHLTHQRLHSR
1815.8879 1815.8359 -0.052 -29 235 250 EKPFRCDTCGKSFGLK
1875.8839 1875.8468 -0.0371 -20 511 526 LHGDEKPFKCEECGKR
1923.9163 1923.8796 -0.0367 -19 240 257 CDTCGKSFGLKSALNSH
R
2077.1301 2077.051 -0.0791 -38 502 519 ASSILNHKRLHGDEKPFK
2211.0684 2210.9856 -0.0828 -37 455 474 VHTGVKPYKCEECGKGF
NSK
2242.979 2243.0322 0.0532 24 464 482 CEECGKGFNSKFNLDMH
QR
2249.1064 2248.9844 -0.122 -54 106 124 SFCYSSALRIHQRVHMG
EK
Spot Idx/Pos 194/H16 7 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
5 hypothetical protein [Homo sapiens] gi|34365255 56551.9 32 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
975.5105 975.512 0.0015 2 319 326 SEVKDEIR
1360.7001 1360.6941 -0.006 -4 295 305 KQMANQKDLER
1491.7537 1491.7567 0.003 2 140 152 ESEESKLDQVLSK
1647.837 1647.8448 0.0078 5 195 209 SGELLALQKEADSMR
1678.8767 1678.8824 0.0057 3 125 137 LVQQEMMFQRLQK
1708.8687 1708.8544 -0.0143 -8 169 182 WCESLEKTLSQTKR
1837.9918 1838.0012 0.0094 5 210 224 ADFSLLRNQFLTERK
1840.9398 1840.9482 0.0084 5 108 122 QQQLQVLQNEIEENK
2034.9912 2034.9933 0.0021 1 160 175 VRTLQEEERWCESLEK
2217.1042 2217.1138 0.0096 4 278 294 RLMKELNQMQYEYTELK
2226.1182 2226.1306 0.0124 6 26 44 DKLSLHNDISAMQQQLQ
EK
2262.1836 2262.1836 0 0 67 85 QDLLHTTKHQDVLLSEQT
R
2338.1509 2338.1682 0.0173 7 377 395 LNFSQVHIMDEHWRGEA
LR
14 HSPA8 protein [Homo sapiens] gi|48257068 64633.1 27 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1199.6742 1199.6604 -0.0138 -12 101 112 DAGTIAGLNVLR
1235.624 1235.632 0.008 6 178 187 MVNHFIAEFK
1252.6605 1252.6497 -0.0108 -9 68 78 MKEIAEAYLGK
1253.616 1253.6311 0.0151 12 243 252 FEELNADLFR
1391.7252 1391.7244 -0.0008 -1 178 188 MVNHFIAEFKR
1480.7543 1480.7609 0.0066 4 241 252 ARFEELNADLFR
1480.7543 1480.7609 0.0066 4 241 252 ARFEELNADLFR
1653.8318 1653.8531 0.0213 13 30 43 HWPFMVVNDAGRPK
1745.8088 1745.7985 -0.0103 -6 525 538 NQTAEKEEFEHQQK
1838.0129 1838.0012 -0.0117 -6 267 283 LDKSQIHDIVLVGGSTR
1952.0599 1952.035 -0.0249 -13 393 410 DNNLLGKFELTGIPPAPR
1981.9977 1981.9973 -0.0004 0 79 96 TVTNAVVTVPAYFNDSQ
R
1981.9977 1981.9973 -0.0004 0 79 96 TVTNAVVTVPAYFNDSQ
R
2774.3267 2774.3303 0.0036 1 365 388 QTQTFTTYSDNQPGVLIQ
VYEGER
2997.4575 2997.4656 0.0081 3 214 240 TLSSSTQASIEIDSLYEGI
DFYTSITR
29 centriole associated protein CEP110 [Homo sapiens] gi|3435244 116741.2 24 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
975.5105 975.512 0.0015 2 831 838 SEVKDEIR
1187.6378 1187.6272 -0.0106 -9 477 487 RVLAAAEENSK
1360.7001 1360.6941 -0.006 -4 807 817 KQMANQKDLER
1443.755 1443.7632 0.0082 6 163 175 ADQQLRSLQADAK
1524.7726 1524.7831 0.0105 7 194 207 IVAAKDSDFQCLSK
1524.7726 1524.7831 0.0105 7 194 207 IVAAKDSDFQCLSK
1551.7496 1551.7626 0.013 8 625 637 ERESEESKLETSK
1647.837 1647.8448 0.0078 5 707 721 SGELLALQKEADSMR
1678.8767 1678.8824 0.0057 3 612 624 LVQQEMMFQRLQK
1708.8687 1708.8544 -0.0143 -8 681 694 WCESLEKTLSQTKR
1799.8955 1799.9078 0.0123 7 41 55 SLECEVEELHRTVQK
1837.9918 1838.0012 0.0094 5 722 736 ADFSLLRNQFLTERK
1840.9398 1840.9482 0.0084 5 595 609 QQQLQVLQNEIEENK
2034.9912 2034.9933 0.0021 1 672 687 VRTLQEEERWCESLEK
2217.1042 2217.1138 0.0096 4 790 806 RLMKELNQMQYEYTELK
2226.1182 2226.1306 0.0124 6 513 531 DKLSLHNDISAMQQQLQ
EK
2262.1836 2262.1836 0 0 554 572 QDLLHTTKHQDVLLSEQT
R
2283.1509 2283.1655 0.0146 6 256 275 SQVTSQQQEMAVLDRQL
GHK
2338.1521 2338.1682 0.0161 7 132 151 FTDAKRSLLQTESDAEEL
ER
33 heat shock 70kDa protein 8 isoform 2 variant [Homo gi|62896815 53466.4 24 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1199.6742 1199.6604 -0.0138 -12 160 171 DAGTIAGLNVLR
1235.624 1235.632 0.008 6 237 246 MVNHFIAEFK
1252.6605 1252.6497 -0.0108 -9 127 137 MKEIAEAYLGK
1253.616 1253.6311 0.0151 12 302 311 FEELNADLFR
1391.7252 1391.7244 -0.0008 -1 237 247 MVNHFIAEFKR
1480.7543 1480.7609 0.0066 4 300 311 ARFEELNADLFR
1480.7543 1480.7609 0.0066 4 300 311 ARFEELNADLFR
1653.8318 1653.8531 0.0213 13 89 102 HWPFMVVNDAGRPK
1838.0129 1838.0012 -0.0117 -6 326 342 LDKSQIHDIVLVGGSTR
1981.9977 1981.9973 -0.0004 0 138 155 TVTNAVVTVPAYFNDSQ
R
1981.9977 1981.9973 -0.0004 0 138 155 TVTNAVVTVPAYFNDSQ
R
2774.3267 2774.3303 0.0036 1 424 447 QTQTFTTYSDNQPGVLIQ
VYEGER
2997.4575 2997.4656 0.0081 3 273 299 TLSSSTQASIEIDSLYEGI
DFYTSITR
Spot Idx/Pos 140/F8 8 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
2 dead box, X isoform [Homo sapiens] gi|25805 73226 44 74.005
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
895.5148 895.5149 0.0001 0 38 44 YIPPHLR
1182.5497 1182.5872 0.0375 32 100 110 GRSDYDGIGSR
1182.5497 1182.5872 0.0375 32 100 110 GRSDYDGIGSR
1300.6392 1300.6202 -0.019 -15 479 488 DREEALHQFR
1300.6392 1300.6202 -0.019 -15 479 488 DREEALHQFR
1320.6793 1320.6575 -0.0218 -17 277 287 ELAVQIYEEAR
1320.6793 1320.6575 -0.0218 -17 277 287 ELAVQIYEEAR
1336.6388 1336.625 -0.0138 -10 352 362 MLDMGFEPQIR
1336.6388 1336.625 -0.0138 -10 352 362 MLDMGFEPQIR
1485.8787 1485.8275 -0.0512 -34 264 276 KQYPISLVLAPTR
1502.7094 1502.7466 0.0372 25 82 95 SSFFSDRGSGSRGR
1524.7804 1524.756 -0.0244 -16 535 548 VGNLGLATSFFNER
1524.7804 1524.756 -0.0244 -16 535 548 VGNLGLATSFFNER
1557.7947 1557.7716 -0.0231 -15 395 407 DFLDEYIFLAVGR
1557.7947 1557.7716 -0.0231 -15 395 407 DFLDEYIFLAVGR
2083.0242 2082.9902 -0.034 -16 512 528 HVINFDLPSDIEEYVHR
2332.2546 2332.1785 -0.0761 -33 231 252 TAAFLLPILSQIYSDGPGE
ALR
8 heterogeneous nuclear ribonucleoprotein M isoform a gi|62089046 65211.2 21 0
variant [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1427.7133 1427.7297 0.0164 11 477 491 MGPAMGPALGAGIER
1613.7773 1613.7665 -0.0108 -7 342 356 MGPLGLDHMASSIER
2034.9528 2034.9397 -0.0131 -6 513 535 GNFGGSFAGSFGGAGG
HAPGVAR
2034.9528 2034.9397 -0.0131 -6 513 535 GNFGGSFAGSFGGAGG
HAPGVAR
2211.05 2211.05 0 0 322 341 MGLVMDRMGSVERMGS
GIER
2283.0896 2283.1208 0.0312 14 558 577 FNECGHVLYADIKMENG
KSK
2286.115 2286.1216 0.0066 3 469 491 MGANSLERMGPAMGPA
LGAGIER
9 golgin-245 [Homo sapiens] gi|1173565 244378.2 48 88.388
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
895.5359 895.5149 -0.021 -23 336 342 LQKLHEK
1104.5782 1104.569 -0.0092 -8 1166 1175 ADIESLVTEK
1104.5782 1104.569 -0.0092 -8 1166 1175 ADIESLVTEK
1182.6224 1182.5872 -0.0352 -30 2 11 ERSLSSYRGK
1182.6224 1182.5872 -0.0352 -30 2 11 ERSLSSYRGK
1233.6508 1233.6006 -0.0502 -41 1508 1517 KQLLSQMEEK
1233.6508 1233.6006 -0.0502 -41 1508 1517 KQLLSQMEEK
1439.7375 1439.7792 0.0417 29 373 384 SQSEYLKISQEK
1439.7375 1439.7792 0.0417 29 373 384 SQSEYLKISQEK
1502.806 1502.7466 -0.0594 -40 838 850 KELENTALELSQK
1524.7903 1524.756 -0.0343 -22 1050 1062 SNKSLEDKSLEFK
1524.7903 1524.756 -0.0343 -22 1050 1062 SNKSLEDKSLEFK
1592.8577 1592.905 0.0473 30 456 468 HNKEITVMVEKHK
1635.8588 1635.8716 0.0128 8 266 280 AAFEELEKALSTAQK
1778.9143 1778.8341 -0.0802 -45 410 423 LRDLQQEAETYRTR
1833.9812 1833.9382 -0.043 -23 1063 1078 KLSEELAIQLDICCKK
1910.9528 1910.9139 -0.0389 -20 1509 1523 QLLSQMEEKEEQYKK
1930.0062 1929.9452 -0.061 -32 44 59 IAELREELQMDQQAKK
1951.0494 1950.9677 -0.0817 -42 1588 1603 TYEEKISVLQRNLTEK
1971.0028 1970.9785 -0.0243 -12 172 187 EALQEQLDERLQELEK
1982.9487 1982.9662 0.0175 9 1913 1928 RYEEILDAREEEMTAK
2078.0083 2077.9739 -0.0344 -17 580 596 MDEQKNHHQQQVDSIIK
2082.0171 2082.0344 0.0173 8 1914 1930 YEEILDAREEEMTAKVR
2084.0518 2083.9934 -0.0584 -28 1981 1996 EQEFREQIHNLEDRLK
2233.1445 2233.0481 -0.0964 -43 534 553 LDVNQTELESLSSELSEV
LK
2256.1177 2256.0205 -0.0972 -43 728 746 QNSEMEQKVKSLTQVYE
SK
Spot Idx/Pos 141/F10 9 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 PRO2446 [Homo sapiens] gi|7959903 27175.8 77 99.988
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1343.7065 1343.7135 0.007 5 183 193 DNTINLIHTFR
1354.726 1354.7419 0.0159 12 52 63 DSIVHQAGMLKR
1450.7549 1450.7675 0.0126 9 136 148 ASHTAPQVLFSHR
1450.7549 1450.7675 0.0126 9 136 148 ASHTAPQVLFSHR
1606.8561 1606.8541 -0.002 -1 135 148 RASHTAPQVLFSHR
1760.7874 1760.7946 0.0072 4 73 86 YFQFQEEGKEGENR
1760.7874 1760.7946 0.0072 4 73 86 YFQFQEEGKEGENR
1918.0181 1918.0171 -0.001 -1 8 23 FYKELQAHGADELLKR
1955.9167 1955.9307 0.014 7 87 102 AVIHYRDDETMYVESK
2083.0957 2083.0916 -0.0041 -2 106 124 VTVVFSTVFKDDDDVVIG
K
2257.2087 2257.2166 0.0079 3 136 155 ASHTAPQVLFSHREPPLE
LK
2257.2087 2257.2166 0.0079 3 136 155 ASHTAPQVLFSHREPPLE
LK
2413.241 2413.2661 0.0251 10 183 201 DNTINLIHTFRDYLHYHIK
2992.5376 2992.5549 0.0173 6 106 131 VTVVFSTVFKDDDDVVIG
KVFMQEFK
3088.5513 3088.5608 0.0095 3 24 51 VYGSFLVNPESGYNVSLL
YDLENLPASK
2 Chain A, Three-Dimensional Structure Of Human gi|2781202 33075.4 77 99.987 13 85.488
Electron Transfer Flavoprotein To 2.1 A Resolution
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1714.8005 1714.8143 0.0138 8 84 99 QFNYTHICAGASAFGK
1736.0204 1736.0052 -0.0152 -9 68 83 GLLPEELTPLILATQK
1736.0204 1736.0052 -0.0152 -9 68 83 GLLPEELTPLILATQK
1751.0676 1751.066 -0.0016 -1 105 121 VAAKLEVAPISDIIAIK
1812.9602 1812.9628 0.0026 1 215 231 LLYDLADQLHAAVGASR
1812.9602 1812.9628 0.0026 1 215 231 LLYDLADQLHAAVGASR 13 85.488
1904.917 1904.9191 0.0021 1 232 250 AAVDAGFVPNDMQVGQT
GK
2351.3154 2351.3098 -0.0056 -2 251 273 IVAPELYIAVGISGAIQHLA
GMK
2475.2625 2475.2732 0.0107 4 209 231 SGENFKLLYDLADQLHAA
VGASR
2475.2625 2475.2732 0.0107 4 209 231 SGENFKLLYDLADQLHAA
VGASR
2553.4648 2553.4614 -0.0034 -1 105 128 VAAKLEVAPISDIIAIKSPD
TFVR
2553.4648 2553.4614 -0.0034 -1 105 128 VAAKLEVAPISDIIAIKSPD
TFVR
2821.5054 2821.5051 -0.0003 0 2 28 QSTLVIAEHANDSLAPITL
NTITAATR
2821.5054 2821.5051 -0.0003 0 2 28 QSTLVIAEHANDSLAPITL
NTITAATR
2888.6494 2888.6521 0.0027 1 58 83 VLVAQHDVYKGLLPEELT
PLILATQK
2947.5813 2947.5933 0.012 4 277 303 TIVAINKDPEAPIFQVADY
GIVADLFK
3 actin related protein 2/3 complex subunit 2 [Homo gi|5031599 34311.5 74 99.975
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1101.6084 1101.6196 0.0112 10 1 9 MILLEVNNR
1101.6084 1101.6196 0.0112 10 1 9 MILLEVNNR
1343.7065 1343.7135 0.007 5 238 248 DNTINLIHTFR
1354.726 1354.7419 0.0159 12 107 118 DSIVHQAGMLKR
1450.7549 1450.7675 0.0126 9 191 203 ASHTAPQVLFSHR
1450.7549 1450.7675 0.0126 9 191 203 ASHTAPQVLFSHR
1606.8561 1606.8541 -0.002 -1 190 203 RASHTAPQVLFSHR
1760.7874 1760.7946 0.0072 4 128 141 YFQFQEEGKEGENR
1760.7874 1760.7946 0.0072 4 128 141 YFQFQEEGKEGENR
1918.0181 1918.0171 -0.001 -1 63 78 FYKELQAHGADELLKR
1955.9167 1955.9307 0.014 7 142 157 AVIHYRDDETMYVESK
2083.0957 2083.0916 -0.0041 -2 161 179 VTVVFSTVFKDDDDVVIG
K
2257.2087 2257.2166 0.0079 3 191 210 ASHTAPQVLFSHREPPLE
LK
2257.2087 2257.2166 0.0079 3 191 210 ASHTAPQVLFSHREPPLE
LK
2413.241 2413.2661 0.0251 10 238 256 DNTINLIHTFRDYLHYHIK
2992.5376 2992.5549 0.0173 6 161 186 VTVVFSTVFKDDDDVVIG
KVFMQEFK
3088.5513 3088.5608 0.0095 3 79 106 VYGSFLVNPESGYNVSLL
YDLENLPASK
Spot Idx/Pos 142/F12 10 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 actin related protein 2/3 complex subunit 2 [Homo gi|5031599 34311.5 113 100 10 72.814
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1101.6084 1101.605 -0.0034 -3 1 9 MILLEVNNR
1101.6084 1101.605 -0.0034 -3 1 9 MILLEVNNR 8 50.643
1270.6248 1270.6273 0.0025 2 180 189 VFMQEFKEGR
1314.7489 1314.7307 -0.0182 -14 55 65 VMVSISLKFYK
1343.7065 1343.7064 -0.0001 0 238 248 DNTINLIHTFR
1354.726 1354.7288 0.0028 2 107 118 DSIVHQAGMLKR
1450.7549 1450.7538 -0.0011 -1 191 203 ASHTAPQVLFSHR
1450.7549 1450.7538 -0.0011 -1 191 203 ASHTAPQVLFSHR
1479.7914 1479.8063 0.0149 10 66 78 ELQAHGADELLKR
1606.8561 1606.8483 -0.0078 -5 190 203 RASHTAPQVLFSHR
1760.7874 1760.7944 0.007 4 128 141 YFQFQEEGKEGENR
1760.7874 1760.7944 0.007 4 128 141 YFQFQEEGKEGENR 3 0
1918.0181 1918.0205 0.0024 1 63 78 FYKELQAHGADELLKR
1955.9167 1955.9294 0.0127 6 142 157 AVIHYRDDETMYVESK
1955.9167 1955.9294 0.0127 6 142 157 AVIHYRDDETMYVESK
2083.0957 2083.0823 -0.0134 -6 161 179 VTVVFSTVFKDDDDVVIG
K
2257.2087 2257.2156 0.0069 3 191 210 ASHTAPQVLFSHREPPLE
LK
2257.2087 2257.2156 0.0069 3 191 210 ASHTAPQVLFSHREPPLE
LK
2413.241 2413.2507 0.0097 4 238 256 DNTINLIHTFRDYLHYHIK
2990.5508 2990.5901 0.0393 13 204 230 EPPLELKDTDAAVGDNIG
YITFVLFPR
3088.5513 3088.5667 0.0154 5 79 106 VYGSFLVNPESGYNVSLL
YDLENLPASK
3 Chain A, Three-Dimensional Structure Of Human gi|2781202 33075.4 92 100 2 0
Electron Transfer Flavoprotein To 2.1 A Resolution
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1171.647 1171.6427 -0.0043 -4 58 67 VLVAQHDVYK
1714.8005 1714.8076 0.0071 4 84 99 QFNYTHICAGASAFGK
1736.0204 1736.0026 -0.0178 -10 68 83 GLLPEELTPLILATQK
1751.0676 1751.057 -0.0106 -6 105 121 VAAKLEVAPISDIIAIK
1776.865 1776.8628 -0.0022 -1 170 185 ASSTSPVEISEWLDQK
1776.865 1776.8628 -0.0022 -1 170 185 ASSTSPVEISEWLDQK 2 0
1812.9602 1812.9636 0.0034 2 215 231 LLYDLADQLHAAVGASR
1812.9602 1812.9636 0.0034 2 215 231 LLYDLADQLHAAVGASR
1904.917 1904.9043 -0.0127 -7 232 250 AAVDAGFVPNDMQVGQT
GK
1904.917 1904.9043 -0.0127 -7 232 250 AAVDAGFVPNDMQVGQT
GK
2119.0918 2119.093 0.0012 1 170 188 ASSTSPVEISEWLDQKLT
K
2351.3154 2351.2976 -0.0178 -8 251 273 IVAPELYIAVGISGAIQHLA
GMK
2475.2625 2475.272 0.0095 4 209 231 SGENFKLLYDLADQLHAA
VGASR
2553.4648 2553.4648 0 0 105 128 VAAKLEVAPISDIIAIKSPD
TFVR
2553.4648 2553.4648 0 0 105 128 VAAKLEVAPISDIIAIKSPD
TFVR
2821.5054 2821.5046 -0.0008 0 2 28 QSTLVIAEHANDSLAPITL
NTITAATR
2821.5054 2821.5046 -0.0008 0 2 28 QSTLVIAEHANDSLAPITL
NTITAATR
2888.6494 2888.6392 -0.0102 -4 58 83 VLVAQHDVYKGLLPEELT
PLILATQK
2947.5813 2947.5796 -0.0017 -1 277 303 TIVAINKDPEAPIFQVADY
GIVADLFK
Spot Idx/Pos 143/F14 11 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 3
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
17 Single-stranded DNA binding protein 1 [Homo sapiens] gi|62205329 17348.1 15 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
883.4995 883.493 -0.0065 -7 39 46 VGQDPVLR
1044.6312 1044.6343 0.0031 3 87 95 ISVFRPGLR
Spot Idx/Pos 144/F16 12 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 Chain A, Human Mitochondrial Single-Stranded Dna gi|2624694 15185.8 99 100
Binding Protein
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
883.4995 883.4959 -0.0036 -4 23 30 VGQDPVLR
1044.6312 1044.6274 -0.0038 -4 71 79 ISVFRPGLR
1164.6959 1164.6891 -0.0068 -6 13 22 SLNRVHLLGR
1616.7373 1616.7599 0.0226 14 98 110 IDYGEYMDKNNVR
1778.8894 1778.9095 0.0201 11 36 50 NPVTIFSLATNEMWR
1992.0647 1992.066 0.0013 1 112 129 QATTIIADNIIFLSDQTK
2148.1658 2148.1343 -0.0315 -15 111 129 RQATTIIADNIIFLSDQTK
2293.0842 2293.0598 -0.0244 -11 51 70 SGDSEVYQLGDVSQKTT
WHR
2320.1753 2320.1577 -0.0176 -8 31 50 QVEGKNPVTIFSLATNEM
WR
2378.2449 2378.2454 0.0005 0 112 132 QATTIIADNIIFLSDQTKEK
E
4 EP2E [Homo sapiens] gi|10799277 9085.3 29 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1422.6763 1422.6794 0.0031 2 27 38 NTICRMQQGICR
1422.6763 1422.6794 0.0031 2 27 38 NTICRMQQGICR
2384.0161 2384.0339 0.0178 7 59 80 CCVSNTDEEGKEKPEMD
GRSGI
3354.7852 3354.7366 -0.0486 -14 2 31 KVFFLFAVLFCLVQTNSG
DVPPGIRNTICR
Spot Idx/Pos 195/H18 13 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 PREDICTED: similar to 60S ribosomal protein L35 gi|51459132 14555.4 48 88.388
[Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
817.5076 817.5087 0.0011 1 1 7 MAKIKAR
823.5009 823.4944 -0.0065 -8 93 98 HRLNKR
825.4941 825.4947 0.0006 1 8 14 DLHGKKK
902.524 902.5374 0.0134 15 111 117 ERLCLLR
924.5373 924.5402 0.0029 3 6 13 ARDLHGKK
946.5468 946.5562 0.0094 10 104 110 TKKQQWK
988.5785 988.5778 -0.0007 -1 33 43 VAKVTGGAASK
995.5857 995.5863 0.0006 1 90 97 ATRHRLNK
1012.5785 1012.5893 0.0108 11 99 106 EEHLKTKK
1018.5891 1018.5967 0.0076 7 36 46 VTGGAASKLSK
1030.6189 1030.6138 -0.0051 -5 111 118 ERLCLLRK
1037.6213 1037.6206 -0.0007 -1 4 12 IKARDLHGK
2 RPL13A protein [Homo sapiens] gi|111494155 16706.4 39 19.667
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
828.5011 828.4939 -0.0072 -9 57 64 MVVPAALK
844.5151 844.514 -0.0011 -1 105 110 IHYRKK
872.5312 872.5234 -0.0078 -9 116 122 LRKQAEK
915.5522 915.5591 0.0069 8 103 109 AKIHYRK
915.5522 915.5591 0.0069 8 103 109 AKIHYRK
971.5632 971.5668 0.0036 4 34 42 GQAALDRLK
973.5676 973.571 0.0034 3 123 130 NVEKKIDK
977.5679 977.5819 0.014 14 18 24 IFWRTVR
977.5679 977.5819 0.014 14 18 24 IFWRTVR
1044.5948 1044.6017 0.0069 7 101 108 EKAKIHYR
1108.6248 1108.631 0.0062 6 128 136 IDKYTEVLK
1267.7303 1267.7238 -0.0065 -5 22 32 TVRGMLPHKTK
2866.4885 2866.5105 0.022 8 74 98 FAYLGRLAHEVGWKYQA
VTATLEDK
3 CCDC71 protein [Homo sapiens] gi|48735006 24879.5 35 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
827.4846 827.4941 0.0095 11 120 126 VARTQPR
845.5025 845.5119 0.0094 11 1 7 PKCLTRK
853.5254 853.513 -0.0124 -15 163 169 DLPPKKR
895.522 895.5322 0.0102 11 7 15 KGPGAGPRR
944.5635 944.5654 0.0019 2 67 75 TQAKAAKAR
945.5662 945.564 -0.0022 -2 100 108 VMAARAKAK
1013.5962 1013.6022 0.006 6 127 136 GRGRPKGSAK
1026.6166 1026.608 -0.0086 -8 118 126 AKVARTQPR
1040.6072 1040.6086 0.0014 1 120 128 VARTQPRGR
1041.6276 1041.613 -0.0146 -14 57 66 AARAQAKVAR
1100.635 1100.6407 0.0057 5 223 232 LQPLLPYSAV
1105.6146 1105.6022 -0.0124 -11 34 44 RMKGGSALGTK
1171.6906 1171.678 -0.0126 -11 60 70 AQAKVARTQAK
1184.6494 1184.6377 -0.0117 -10 146 155 NRPETVGQKR
6 PREDICTED: similar to H3 histone, family 3B [Homo gi|88976633 15216.4 32 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
832.4999 832.4979 -0.002 -2 4 10 TKQTARK
844.5073 844.514 0.0067 8 117 123 RVTIMPK
858.5155 858.5172 0.0017 2 20 27 QLATKAAR
931.5432 931.5523 0.0091 10 2 9 ARTKQTAR
945.5727 945.564 -0.0087 -9 58 65 STELLVRK
992.5635 992.5674 0.0039 4 51 57 EIRRYQK
1032.5948 1032.6097 0.0149 14 42 50 YRPGTVALR
1052.5847 1052.5978 0.0131 12 124 132 DIQLAHSIR
1218.6841 1218.6906 0.0065 5 71 80 LVREIAQDFK
1229.6959 1229.6937 -0.0022 -2 25 37 AARKSAPSTGGVK
25 PREDICTED: similar to ribosomal protein L13a isoform gi|89037070 23428.2 26 0
1 [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
813.5305 813.533 0.0025 3 26 32 QVLLGRK
844.5151 844.514 -0.0011 -1 166 171 IHYRKK
872.5312 872.5234 -0.0078 -9 177 183 LRKQAEK
915.5522 915.5591 0.0069 8 164 170 AKIHYRK
915.5522 915.5591 0.0069 8 164 170 AKIHYRK
971.5632 971.5668 0.0036 4 95 103 GQAALDRLK
973.5676 973.571 0.0034 3 184 191 NVEKKIDK
1018.5865 1018.5967 0.0102 10 117 125 RMVVPAAFK
1044.5948 1044.6017 0.0069 7 162 169 EKAKIHYR
1108.6248 1108.631 0.0062 6 189 197 IDKYTEVLK
1267.7303 1267.7238 -0.0065 -5 83 93 TVRGMLPHKTK
2000.009 2000.002 -0.007 -3 32 49 KVVVVCCEGINISGNFYR
Spot Idx/Pos 146/F20 14 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
11 H1 histone family, member 0 [Homo sapiens] gi|20810 20872.2 21 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
870.577 870.5884 0.0114 13 162 169 TVKAKPVK
895.6087 895.6135 0.0048 5 175 182 KAKPVKPK
899.6036 899.61 0.0064 7 157 164 AKKPKTVK
966.6458 966.6421 -0.0037 -4 176 184 AKPVKPKAK
986.6356 986.6431 0.0075 8 74 82 RLVTTGVLK
996.6564 996.6554 -0.001 -1 137 145 KPKATPVKK
1053.6779 1053.6901 0.0122 12 165 174 AKPVKASKPK
Spot Idx/Pos 147/F22 15 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
2 ARP3 actin-related protein 3 homolog [Homo sapiens] gi|5031573 47341 38 0 2 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
958.5792 958.5829 0.0037 4 341 348 RTVDARLK
1214.5687 1214.5781 0.0094 8 266 275 EFSIDVGYER
1409.7787 1409.7894 0.0107 8 199 209 DITYFIQQLLR
1409.7787 1409.7894 0.0107 8 199 209 DITYFIQQLLR 2 0
1499.6947 1499.7078 0.0131 9 80 91 HGIVEDWDLMER
1499.6947 1499.7078 0.0131 9 80 91 HGIVEDWDLMER
1768.9075 1768.9175 0.01 6 210 225 DREVGIPPEQSLETAK
1769.9254 1769.9199 -0.0055 -3 226 240 AVKERYSYVCPDLVK
1795.9799 1795.9689 -0.011 -6 212 228 EVGIPPEQSLETAKAVK
1912.981 1912.9827 0.0017 1 318 334 NIVLSGGSTMFRDFGRR
2154.2183 2154.1975 -0.0208 -10 192 209 HIPIAGRDITYFIQQLLR
2482.1885 2482.1809 -0.0076 -3 103 123 AEPEDHYFLLTEPPLNTP
ENR
2482.1885 2482.1809 -0.0076 -3 103 123 AEPEDHYFLLTEPPLNTP
ENR
4 translation initiation factor [Homo sapiens] gi|496902 46803.1 38 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1159.647 1159.6617 0.0147 13 330 339 VLISTDVWAR
1212.6946 1212.7087 0.0141 12 106 116 ETQALILAPTR
1417.7109 1417.7208 0.0099 7 196 206 GFKEQIYDVYR
1469.7495 1469.7535 0.004 3 153 166 LDYGQHVVAGTPGR
1588.8805 1588.8656 -0.0149 -9 374 387 KGVAINFVKNDDIR
1827.9387 1827.9484 0.0097 5 52 67 GIYAYGFEKPSAIQQR
1827.9387 1827.9484 0.0097 5 52 67 GIYAYGFEKPSAIQQR
1994.0592 1994.0331 -0.0261 -13 244 260 DELTLEGIKQFFVAVER
2140.1396 2140.1401 0.0005 0 340 358 GLDVPQVSLIINYDLPNN
R
2140.1548 2140.1401 -0.0147 -7 52 70 GIYAYGFEKPSAIQQRAIK
2870.395 2870.373 -0.022 -8 388 411 ILRDIEQYYSTQIDEMPM
NVADLI
5 Growth-arrest-specific protein 7 (GAS-7) gi|12643625 47236.7 36 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
873.4901 873.4961 0.006 7 278 284 ALTERQR
1393.7321 1393.7365 0.0044 3 179 189 ERIKIEEDYAK
1478.8074 1478.7898 -0.0176 -12 264 276 QLASRYASVEKAR
1644.8591 1644.8368 -0.0223 -14 217 231 SLADEAEVHLKFSAK
1707.8507 1707.8685 0.0178 10 87 103 KSTGDSQNLGSSSPSKK
1759.937 1759.913 -0.024 -14 283 296 QRDLEMKTQQLEIK
1762.9128 1762.9265 0.0137 8 254 268 CDHHIADLRKQLASR
1772.954 1772.9673 0.0133 8 216 231 KSLADEAEVHLKFSAK
1786.9333 1786.9213 -0.012 -7 146 162 DPQGNGTVAGFELLLQK
2460.2363 2460.2466 0.0103 4 194 216 LSQNSLASQEEGSLGEA
WAQVKK
15 translation elongation factor 1 alpha 1-like 14 [Homo gi|15277711 42997.3 28 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1025.6101 1025.6255 0.0154 15 192 202 IGGIGTVPVGR
1314.7416 1314.7347 -0.0069 -5 71 82 EHALLAYTLGVK
1316.7355 1316.7366 0.0011 1 364 375 DMRQTVAVGVIK
1404.7269 1404.7406 0.0137 10 21 32 YYVTIIDAPGHR
1776.9313 1776.9458 0.0145 8 1 15 MQSERGITIDISLWK
1908.0013 1908.0121 0.0108 6 21 36 YYVTIIDAPGHRDFIK
1908.0013 1908.0121 0.0108 6 21 36 YYVTIIDAPGHRDFIK
2515.3838 2515.3674 -0.0164 -7 203 226 VETGVLKPGMVVTFAPV
NVTTEVK
2515.3838 2515.3674 -0.0164 -7 203 226 VETGVLKPGMVVTFAPV
NVTTEVK
2938.3782 2938.3569 -0.0213 -7 332 359 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
2938.3782 2938.3569 -0.0213 -7 332 359 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
Spot Idx/Pos 148/F24 16 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
3 ARP3 actin-related protein 3 homolog [Homo sapiens] gi|5031573 47341 37 0 4 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1214.5687 1214.5735 0.0048 4 266 275 EFSIDVGYER
1281.6619 1281.6547 -0.0072 -6 318 329 NIVLSGGSTMFR
1409.7787 1409.7798 0.0011 1 199 209 DITYFIQQLLR
1409.7787 1409.7798 0.0011 1 199 209 DITYFIQQLLR 4 0
1499.6947 1499.6978 0.0031 2 80 91 HGIVEDWDLMER
1499.6947 1499.6978 0.0031 2 80 91 HGIVEDWDLMER
1768.9075 1768.9159 0.0084 5 210 225 DREVGIPPEQSLETAK
1795.9799 1795.9746 -0.0053 -3 212 228 EVGIPPEQSLETAKAVK
2040.1534 2040.1238 -0.0296 -15 358 374 LKPKPIDVQVITHHMQR
2154.2183 2154.1868 -0.0315 -15 192 209 HIPIAGRDITYFIQQLLR
2482.1885 2482.1848 -0.0037 -1 103 123 AEPEDHYFLLTEPPLNTP
ENR
2482.1885 2482.1848 -0.0037 -1 103 123 AEPEDHYFLLTEPPLNTP
ENR
2954.469 2954.4314 -0.0376 -13 80 102 HGIVEDWDLMERFMEQV
IFKYLR
4 translation initiation factor [Homo sapiens] gi|496902 46803.1 36 0 2 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1159.647 1159.6421 -0.0049 -4 330 339 VLISTDVWAR
1262.6772 1262.6842 0.007 6 16 25 RLLKEEDMTK
1417.7109 1417.7123 0.0014 1 196 206 GFKEQIYDVYR
1469.7495 1469.7374 -0.0121 -8 153 166 LDYGQHVVAGTPGR
1567.7903 1567.7986 0.0083 5 253 264 QFFVAVEREEWK
1597.8445 1597.84 -0.0045 -3 152 166 KLDYGQHVVAGTPGR
1640.8207 1640.8435 0.0228 14 1 16 MATTATMATSGSARKR
1827.9387 1827.9415 0.0028 2 52 67 GIYAYGFEKPSAIQQR
1827.9387 1827.9415 0.0028 2 52 67 GIYAYGFEKPSAIQQR
2140.1396 2140.1318 -0.0078 -4 340 358 GLDVPQVSLIINYDLPNN
R
2140.1396 2140.1318 -0.0078 -4 340 358 GLDVPQVSLIINYDLPNN 3 0
R
3489.665 3489.6687 0.0037 1 17 46 LLKEEDMTKVEFETSEEV
DVTPTFDTMGLR
6 translation elongation factor 1 alpha 1-like 14 [Homo gi|15277711 42997.3 34 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1025.6101 1025.6062 -0.0039 -4 192 202 IGGIGTVPVGR
1314.7416 1314.7267 -0.0149 -11 71 82 EHALLAYTLGVK
1314.7416 1314.7267 -0.0149 -11 71 82 EHALLAYTLGVK
1404.7269 1404.729 0.0021 1 21 32 YYVTIIDAPGHR
1776.9313 1776.9452 0.0139 8 1 15 MQSERGITIDISLWK
1908.0013 1907.9967 -0.0046 -2 21 36 YYVTIIDAPGHRDFIK
1997.0126 1997.0341 0.0215 11 16 32 FETSKYYVTIIDAPGHR
2515.3838 2515.387 0.0032 1 203 226 VETGVLKPGMVVTFAPV
NVTTEVK
2515.3838 2515.387 0.0032 1 203 226 VETGVLKPGMVVTFAPV
NVTTEVK
2852.4167 2852.4299 0.0132 5 37 65 NMITGTSQADCAVLIVAA
GVGEFEAGISK
2938.3782 2938.3789 0.0007 0 332 359 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
2938.3782 2938.3789 0.0007 0 332 359 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
11 phosphogluconate dehydrogenase [Homo sapiens] gi|40068518 53105.9 27 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1411.7766 1411.7815 0.0049 3 332 343 IISYAQGFMLLR
1493.7893 1493.7993 0.01 7 435 447 HEMLPASLIQAQR
1591.8074 1591.8191 0.0117 7 120 136 GILFVGSGVSGGEEGAR
1790.9393 1790.9468 0.0075 4 118 136 AKGILFVGSGVSGGEEG
AR
2160.1182 2160.1196 0.0014 1 88 107 LVPLLDTGDIIIDGGNSEY
R
2310.1399 2310.1406 0.0007 0 378 396 DAFDRNPELQNLLLDDFF
K
2463.3281 2463.311 -0.0171 -7 266 288 WTAISALEYGVPVTLIGE
AVFAR
2551.3191 2551.3152 -0.0039 -2 376 396 IKDAFDRNPELQNLLLDD
FFK
2595.1863 2595.2024 0.0161 6 185 206 MVHNGIEYGDMQLICEAY
HLMK
13 glucocorticoid receptor AF-1 specific elongation factor gi|7108915 46240 27 0
[Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1025.6101 1025.6062 -0.0039 -4 220 230 IGGIGTVPVGR
1314.7416 1314.7267 -0.0149 -11 99 110 EHALLAYTLGVK
1314.7416 1314.7267 -0.0149 -11 99 110 EHALLAYTLGVK
1404.7269 1404.729 0.0021 1 49 60 YYVTIIDAPGHR
1908.0013 1907.9967 -0.0046 -2 49 64 YYVTIIDAPGHRDFIK
1997.0126 1997.0341 0.0215 11 44 60 FETSKYYVTIIDAPGHR
2515.3838 2515.387 0.0032 1 231 254 VETGVLKPGMVVTFAPV
NVTTEVK
2515.3838 2515.387 0.0032 1 231 254 VETGVLKPGMVVTFAPV
NVTTEVK
2852.4167 2852.4299 0.0132 5 65 93 NMITGTSQADCAVLIVAA
GVGEFEAGISK
2938.3782 2938.3789 0.0007 0 360 387 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
2938.3782 2938.3789 0.0007 0 360 387 SGDAAIVDMVPGKPMCV
ESFSDYPPLGR
Spot Idx/Pos 161/G2 17 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 electron-transfer-flavoprotein, beta polypeptide isoform gi|4503609 27826.2 135 100 14 78.09
1 [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
828.5301 828.5347 0.0046 6 249 255 LKEIGRI
853.5253 853.5312 0.0059 7 99 106 LGPLQVAR
1050.5652 1050.5626 -0.0026 -2 192 200 YATLPNIMK
1054.6255 1054.6179 -0.0076 -7 177 186 LPAVVTADLR
1102.5739 1102.5786 0.0047 4 165 174 EIDGGLETLR
1102.5739 1102.5786 0.0047 4 165 174 EIDGGLETLR 4 0
1295.8044 1295.8088 0.0044 3 175 186 LKLPAVVTADLR
1295.8044 1295.8088 0.0044 3 175 186 LKLPAVVTADLR 5 0
1339.7216 1339.7217 0.0001 0 222 233 LSVISVEDPPQR
1339.7216 1339.7217 0.0001 0 222 233 LSVISVEDPPQR
1403.7277 1403.735 0.0073 5 86 98 GIHVEVPPAEAER 5 0
1403.7277 1403.735 0.0073 5 86 98 GIHVEVPPAEAER
1470.8274 1470.8271 -0.0003 0 22 35 VKPDRTGVVTDGVK
1486.7859 1486.7898 0.0039 3 162 174 VEREIDGGLETLR
1554.9464 1554.9446 -0.0018 -1 111 124 LAEKEKVDLVLLGK
1683.9526 1683.9391 -0.0135 -8 206 221 IEVIKPGDLGVDLTSK
1831.8464 1831.8707 0.0243 13 36 51 HSMNPFCEIAVEEAVR
1831.8464 1831.8707 0.0243 13 36 51 HSMNPFCEIAVEEAVR
1905.1279 1905.1251 -0.0028 -1 175 191 LKLPAVVTADLRLNEPR
2238.2351 2238.2393 0.0042 2 86 106 GIHVEVPPAEAERLGPLQ
VAR
2688.3118 2688.3362 0.0244 9 27 51 TGVVTDGVKHSMNPFCEI
AVEEAVR
4 PREDICTED: similar to Adenylate kinase isoenzyme 4, gi|113423642 25224.2 84 99.998 7 5.016
mitochondrial (Adenylate kinase 3-like 1) (ATP-
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
949.5002 949.506 0.0058 6 127 134 WIHPPSGR
949.5002 949.506 0.0058 6 127 134 WIHPPSGR
1045.5524 1045.5605 0.0081 8 93 102 TLGQAEALDK
1105.6013 1105.6149 0.0136 12 126 134 RWIHPPSGR
1122.5282 1122.5358 0.0076 7 72 80 LMMSELENR
1122.5282 1122.5358 0.0076 7 72 80 LMMSELENR
1249.7262 1249.7363 0.0101 8 61 71 SLLVPDHVITR 4 0
1249.7262 1249.7363 0.0101 8 61 71 SLLVPDHVITR
1278.6293 1278.6471 0.0178 14 72 81 LMMSELENRR
1325.6749 1325.6909 0.016 12 82 92 GQHWLLDGFPR
1325.6749 1325.6909 0.016 12 82 92 GQHWLLDGFPR 3 0
1639.8948 1639.9193 0.0245 15 8 24 AVILGPPGSGKGTVCQR
1925.0139 1925.0304 0.0165 9 25 41 IAQNFGLQHLSSGHFLR
1925.0139 1925.0304 0.0165 9 25 41 IAQNFGLQHLSSGHFLR
2409.2786 2409.2932 0.0146 6 25 45 IAQNFGLQHLSSGHFLRE
NIK
3984.936 3984.9592 0.0232 6 135 170 VYNLDFNPPHVHGIDDVT
GEPLVQQEDDKPEAVAA
R
Spot Idx/Pos 162/G4 18 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 electron-transfer-flavoprotein, beta polypeptide isoform gi|4503609 27826.2 92 100 24 97.868
1 [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
853.5253 853.5281 0.0028 3 99 106 LGPLQVAR
1102.5739 1102.5658 -0.0081 -7 165 174 EIDGGLETLR
1102.5739 1102.5658 -0.0081 -7 165 174 EIDGGLETLR
1295.8044 1295.8074 0.003 2 175 186 LKLPAVVTADLR
1295.8044 1295.8074 0.003 2 175 186 LKLPAVVTADLR 18 90.519
1339.7216 1339.7192 -0.0024 -2 222 233 LSVISVEDPPQR
1339.7216 1339.7192 -0.0024 -2 222 233 LSVISVEDPPQR
1403.7277 1403.7322 0.0045 3 86 98 GIHVEVPPAEAER
1403.7277 1403.7322 0.0045 3 86 98 GIHVEVPPAEAER 6 0
1831.8464 1831.8613 0.0149 8 36 51 HSMNPFCEIAVEEAVR
1831.8464 1831.8613 0.0149 8 36 51 HSMNPFCEIAVEEAVR
1905.1279 1905.1244 -0.0035 -2 175 191 LKLPAVVTADLRLNEPR
1905.1279 1905.1244 -0.0035 -2 175 191 LKLPAVVTADLRLNEPR
2238.2351 2238.2378 0.0027 1 86 106 GIHVEVPPAEAERLGPLQ
VAR
2290.1606 2290.1719 0.0113 5 77 98 TALAMGADRGIHVEVPPA
EAER
4 PREDICTED: similar to Adenylate kinase isoenzyme 4, gi|113423642 25224.2 69 99.906
mitochondrial (Adenylate kinase 3-like 1) (ATP-
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
949.5002 949.5016 0.0014 1 127 134 WIHPPSGR
949.5002 949.5016 0.0014 1 127 134 WIHPPSGR
1105.6013 1105.5948 -0.0065 -6 126 134 RWIHPPSGR
1249.7262 1249.7294 0.0032 3 61 71 SLLVPDHVITR
1249.7262 1249.7294 0.0032 3 61 71 SLLVPDHVITR
1278.6293 1278.6423 0.013 10 72 81 LMMSELENRR
1325.6749 1325.6772 0.0023 2 82 92 GQHWLLDGFPR
1325.6749 1325.6772 0.0023 2 82 92 GQHWLLDGFPR
1481.776 1481.7815 0.0055 4 81 92 RGQHWLLDGFPR
1639.8948 1639.8844 -0.0104 -6 8 24 AVILGPPGSGKGTVCQR
1925.0139 1925.0172 0.0033 2 25 41 IAQNFGLQHLSSGHFLR
1925.0139 1925.0172 0.0033 2 25 41 IAQNFGLQHLSSGHFLR
2409.2786 2409.2827 0.0041 2 25 45 IAQNFGLQHLSSGHFLRE
NIK
Spot Idx/Pos 163/G6 19 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 7
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
Spot Idx/Pos 164/G8 20 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
3 myosin, heavy polypeptide 9, non-muscle [Homo gi|12667788 226391.6 33 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1045.571 1045.5795 0.0085 8 1558 1566 LEVNLQAMK
1155.6632 1155.6715 0.0083 7 1924 1933 GDLPFVVPRR
1155.6632 1155.6715 0.0083 7 1923 1932 RGDLPFVVPR
1524.8057 1524.8043 -0.0014 -1 290 301 TDLLLEPYNKYR
1558.8588 1558.8754 0.0166 11 719 731 QRYEILTPNSIPK
1571.854 1571.8658 0.0118 8 374 387 VSHLLGINVTDFTR
1571.854 1571.8658 0.0118 8 374 387 VSHLLGINVTDFTR
1579.8438 1579.834 -0.0098 -6 765 778 AGVLAHLEEERDLK
1615.8181 1615.8287 0.0106 7 328 341 IMGIPEEEQMGLLR
1615.8181 1615.8287 0.0106 7 328 341 IMGIPEEEQMGLLR
1623.839 1623.8448 0.0058 4 706 718 QGFPNRVVFQEFR
1643.8097 1643.8097 0 0 1 14 MAQQAADKYLYVDK
1643.8097 1643.8097 0 0 1 14 MAQQAADKYLYVDK
1727.856 1727.8778 0.0218 13 126 139 NLPIYSEEIVEMYK
1815.9082 1815.9271 0.0189 10 1816 1830 IAQLEEQLDNETKER
1869.9664 1869.9609 -0.0055 -3 1755 1770 ANLQIDQINTDLNLER
1949.9927 1950.0028 0.0101 5 1418 1433 LQQELDDLLVDLDHQR
1949.9927 1950.0028 0.0101 5 1418 1433 LQQELDDLLVDLDHQR
2048.9626 2048.9705 0.0079 4 1677 1694 SMEAEMIQLQEELAAAER
2048.9626 2048.9705 0.0079 4 1677 1694 SMEAEMIQLQEELAAAER
2299.1345 2299.1677 0.0332 14 1175 1193 TLEEEAKTHEAQIQEMRQ
K
2333.0562 2333.0798 0.0236 10 941 959 MQQNIQELEEQLEEEES
AR
2749.3274 2749.3521 0.0247 9 1302 1324 DFSALESQLQDTQELLQE
ENRQK
3017.4797 3017.47 -0.0097 -3 1136 1162 DLGEELEALKTELEDTLD
STAAQQELR
7 KIAA0678 protein [Homo sapiens] gi|71891673 255972.3 30 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1045.5887 1045.5795 -0.0092 -9 105 113 TELLTEALR
1083.5656 1083.5759 0.0103 10 1406 1414 YAGYPMLIR
1491.7437 1491.7435 -0.0002 0 1457 1469 ENGLEVLQEAFSR
1504.6854 1504.708 0.0226 15 864 874 SYEFFNELYHR
1504.6854 1504.708 0.0226 15 864 874 SYEFFNELYHR
1513.7756 1513.7799 0.0043 3 114 126 FRTDFSEGKITGR
1550.7849 1550.7935 0.0086 6 225 236 EPLEFEQYLNLR
1586.8285 1586.8195 -0.009 -6 207 221 SAIDHAGNYIGISLR
1586.8285 1586.8195 -0.009 -6 207 221 SAIDHAGNYIGISLR
1643.7958 1643.8097 0.0139 8 627 640 HLHTAMFTISSDQR
1643.7958 1643.8097 0.0139 8 627 640 HLHTAMFTISSDQR
1647.8448 1647.8569 0.0121 7 1456 1469 RENGLEVLQEAFSR
1699.9026 1699.9037 0.0011 1 1 14 GWSLSSLPRRFEHK
1712.9329 1712.9464 0.0135 8 193 206 LHLFASEQREEIIK
1736.8754 1736.8877 0.0123 7 375 390 FLATPPNGNFADAVFR
1736.8754 1736.8877 0.0123 7 375 390 FLATPPNGNFADAVFR
1916.9487 1916.96 0.0113 6 240 256 YSTDESITSLAEFVVQK
1940.0269 1940.0266 -0.0003 0 967 984 ATVPLQSNVIEAAPDMKR
1948.0176 1948.0352 0.0176 9 2099 2116 AMASLETIGPLMNGMKK
R
1958.9817 1958.9923 0.0106 5 1603 1620 LGGYLAEEQATPENPTIR
2087.0767 2087.0789 0.0022 1 1603 1621 LGGYLAEEQATPENPTIR
K
2110.0637 2110.072 0.0083 4 357 374 WGLLSMPVDEEVESLHL
R
2266.219 2266.2039 -0.0151 -7 140 160 KPVILEVTPGGFDQINPA
TNR
2266.219 2266.2039 -0.0151 -7 140 160 KPVILEVTPGGFDQINPA
TNR
2511.334 2511.3438 0.0098 4 669 691 ILPPGLLAYLESSDLVPEK
DADR
11 DnaJ (Hsp40) homolog, subfamily C, member 13 gi|112421122 254252.4 26 0
[Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1045.5887 1045.5795 -0.0092 -9 91 99 TELLTEALR
1083.5656 1083.5759 0.0103 10 1392 1400 YAGYPMLIR
1491.7437 1491.7435 -0.0002 0 1443 1455 ENGLEVLQEAFSR
1504.6854 1504.708 0.0226 15 850 860 SYEFFNELYHR
1504.6854 1504.708 0.0226 15 850 860 SYEFFNELYHR
1513.7756 1513.7799 0.0043 3 100 112 FRTDFSEGKITGR
1550.7849 1550.7935 0.0086 6 211 222 EPLEFEQYLNLR
1586.8285 1586.8195 -0.009 -6 193 207 SAIDHAGNYIGISLR
1586.8285 1586.8195 -0.009 -6 193 207 SAIDHAGNYIGISLR
1643.7958 1643.8097 0.0139 8 613 626 HLHTAMFTISSDQR
1643.7958 1643.8097 0.0139 8 613 626 HLHTAMFTISSDQR
1647.8448 1647.8569 0.0121 7 1442 1455 RENGLEVLQEAFSR
1712.9329 1712.9464 0.0135 8 179 192 LHLFASEQREEIIK
1736.8754 1736.8877 0.0123 7 361 376 FLATPPNGNFADAVFR
1736.8754 1736.8877 0.0123 7 361 376 FLATPPNGNFADAVFR
1916.9487 1916.96 0.0113 6 226 242 YSTDESITSLAEFVVQK
1940.0269 1940.0266 -0.0003 0 953 970 ATVPLQSNVIEAAPDMKR
1948.0176 1948.0352 0.0176 9 2085 2102 AMASLETIGPLMNGMKK
R
1958.9817 1958.9923 0.0106 5 1589 1606 LGGYLAEEQATPENPTIR
2087.0767 2087.0789 0.0022 1 1589 1607 LGGYLAEEQATPENPTIR
K
2110.0637 2110.072 0.0083 4 343 360 WGLLSMPVDEEVESLHL
R
2266.219 2266.2039 -0.0151 -7 126 146 KPVILEVTPGGFDQINPA
TNR
2266.219 2266.2039 -0.0151 -7 126 146 KPVILEVTPGGFDQINPA
TNR
2511.334 2511.3438 0.0098 4 655 677 ILPPGLLAYLESSDLVPEK
DADR
Spot Idx/Pos 165/G10 21 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 [Homo gi|4826686 82379.8 82 99.996 7 35.986
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
975.5006 975.5065 0.0059 6 452 458 TDRLWER
1048.6149 1048.6255 0.0106 10 491 499 ILKGEYAVR
1111.6832 1111.6978 0.0146 13 320 330 ELLIIGGVAAR
1111.6832 1111.6978 0.0146 13 320 330 ELLIIGGVAAR 7 35.986
1380.8684 1380.8784 0.01 7 318 330 LRELLIIGGVAAR
1386.7239 1386.7271 0.0032 2 422 432 IMHFPTWVDLK
1467.7664 1467.7736 0.0072 5 211 223 DLGLAFEIPPHMK
1610.8068 1610.8232 0.0164 10 387 400 MHNQIPQVTSDGKR
1663.8948 1663.8997 0.0049 3 563 577 KGDVRFLICTDVAAR
1766.9258 1766.9036 -0.0222 -13 208 223 NGKDLGLAFEIPPHMK
1916.0421 1916.0293 -0.0128 -7 400 416 RLQVIVCSATLHSFDVK
1968.0396 1968.0426 0.003 2 331 349 DQLSVLENGVDIVVGTPG
R
1968.0396 1968.0426 0.003 2 331 349 DQLSVLENGVDIVVGTPG
R
2002.9287 2002.9384 0.0097 5 473 490 DNTRPGANSPEMWSEAI
K
2002.9287 2002.9384 0.0097 5 473 490 DNTRPGANSPEMWSEAI
K
2025.0399 2025.0447 0.0048 2 433 451 GEDSVPDTVHHVVVPVN
PK
2079.1121 2079.1104 -0.0017 -1 578 596 GIDIHGVPYVINVTLPDEK
2134.1079 2134.1169 0.009 4 721 738 EAQTSFLHLGYLPNQLFR
2134.1079 2134.1169 0.009 4 721 738 EAQTSFLHLGYLPNQLFR
2138.1814 2138.1704 -0.011 -5 289 307 ALIVEPSRELAEQTLNNIK
2372.1768 2372.178 0.0012 1 366 386 FLVLDEADGLLSQGYSDF
INR
2372.1768 2372.178 0.0012 1 366 386 FLVLDEADGLLSQGYSDF
INR
2876.5051 2876.4907 -0.0144 -5 578 602 GIDIHGVPYVINVTLPDEK
QNYVHR
2876.5051 2876.4907 -0.0144 -5 578 602 GIDIHGVPYVINVTLPDEK
QNYVHR
2896.5261 2896.4885 -0.0376 -13 331 358 DQLSVLENGVDIVVGTPG
RLDDLVSTGK
3 chaperone protein HSP90 beta [Homo sapiens] gi|9082289 72827.8 58 98.916
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
829.5505 829.5417 -0.0088 -11 106 112 VKEVVKK
886.5468 886.5516 0.0048 5 358 364 RLSELLR
1236.6371 1236.6489 0.0118 10 246 255 RAPFDLFENK
1237.6283 1237.6427 0.0144 12 77 88 ADHGEPIGRGTK
1348.6643 1348.6775 0.0132 10 228 238 HFSVEGQLEFR
1348.6643 1348.6775 0.0132 10 228 238 HFSVEGQLEFR
1513.7856 1513.8082 0.0226 15 287 300 GVVDSEDLPLNISR
1649.8744 1649.8676 -0.0068 -4 180 192 IKEKYIDQEELNK
1782.9497 1782.9545 0.0048 3 533 547 HLEINPDHPIVETLR
1782.9497 1782.9545 0.0048 3 533 547 HLEINPDHPIVETLR
1808.9581 1808.9552 -0.0029 -2 113 127 HSQFIGYPITLYLEK
1911.0446 1911.0511 0.0065 3 532 547 KHLEINPDHPIVETLR
2015.0443 2015.0457 0.0014 1 89 104 VILHLKEDQTEYLEER
2015.0443 2015.0457 0.0014 1 89 104 VILHLKEDQTEYLEER
2171.1455 2171.146 0.0005 0 89 105 VILHLKEDQTEYLEERR
2176.9451 2176.9678 0.0227 10 365 383 YHTSQSGDEMTSLSEYV
SR
2176.9451 2176.9678 0.0227 10 365 383 YHTSQSGDEMTSLSEYV
SR
2255.9587 2255.9744 0.0157 7 57 76 HNDDEQYAWESSAGGS
FTVR
2255.9587 2255.9744 0.0157 7 57 76 HNDDEQYAWESSAGGS
FTVR
2317.1243 2317.0999 -0.0244 -11 268 286 VFIMDSCDELIPEYLNFIR
2391.1826 2391.1809 -0.0017 -1 390 410 SIYYITGESKEQVANSAF
VER
4 ribonucleotide reductase M1 subunit [Homo sapiens] gi|5006420 89984.5 58 98.839
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1096.5819 1096.5847 0.0028 3 13 21 VMFDKITSR
1126.6003 1126.6104 0.0101 9 71 80 HPDYAILAAR
1344.748 1344.7441 -0.0039 -3 119 130 STLDIVLANKDR
1367.7035 1367.7137 0.0102 7 163 173 VAERPQHMLMR
1367.7035 1367.7137 0.0102 7 163 173 VAERPQHMLMR
1509.7842 1509.7776 -0.0066 -4 10 21 QERVMFDKITSR
1570.87 1570.869 -0.001 -1 741 754 TRPAANPIQFTLNK
1693.9635 1693.9425 -0.021 -12 629 643 VLSGEFQIVNPHLLK
1828.0074 1827.9912 -0.0162 -9 741 756 TRPAANPIQFTLNKEK
1850.0646 1850.0602 -0.0044 -2 628 643 RVLSGEFQIVNPHLLK
2064.1533 2064.1414 -0.0119 -6 498 516 HRPIGIGVQGLADAFILM
R
2093.0444 2093.0535 0.0091 4 257 277 ATGSYIAGTNGNSNGLVP
MLR
2108.0845 2108.0823 -0.0022 -1 480 497 IIDINYYPVPEACLSNKR
2302.1462 2302.1604 0.0142 6 699 719 GAFIDQSQSLNIHIAEPNY
GK
2333.1235 2333.1125 -0.011 -5 131 149 LNSAIIYDRDFSYNYFGFK
2391.2019 2391.1809 -0.021 -9 140 158 DFSYNYFGFKTLERSYLL
K
2572.3252 2572.3203 -0.0049 -2 174 196 VSVGIHKEDIDAAIETYNL
LSER
3579.7998 3579.7856 -0.0142 -4 595 627 NSLLIAPMPTASTAQILGN
NESIEPYTSNIYTR
Spot Idx/Pos 166/G12 22 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 heat shock 90kDa protein 1, beta [Homo sapiens] gi|20149594 83212.1 134 100 1 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
829.5294 829.5364 0.007 8 331 337 ALLFIPR
886.5468 886.5482 0.0014 2 450 456 RLSELLR
901.5254 901.524 -0.0014 -2 285 291 TKPIWTR
1194.6477 1194.6538 0.0061 5 73 82 IDIIPNPQER
1236.6371 1236.6494 0.0123 10 338 347 RAPFDLFENK
1249.6171 1249.635 0.0179 14 492 502 EQVANSAFVER
1348.6643 1348.6707 0.0064 5 320 330 HFSVEGQLEFR
1348.6643 1348.6707 0.0064 5 320 330 HFSVEGQLEFR 1 0
1364.7321 1364.7297 -0.0024 -2 338 348 RAPFDLFENKK
1513.7856 1513.7952 0.0096 6 379 392 GVVDSEDLPLNISR
1513.7856 1513.7952 0.0096 6 379 392 GVVDSEDLPLNISR
1544.8278 1544.8197 -0.0081 -5 42 55 ELISNASDALDKIR
1564.8693 1564.8527 -0.0166 -11 70 82 ELKIDIIPNPQER
1649.8744 1649.8595 -0.0149 -9 272 284 IKEKYIDQEELNK
1782.9497 1782.9604 0.0107 6 625 639 HLEINPDHPIVETLR
1782.9497 1782.9604 0.0107 6 625 639 HLEINPDHPIVETLR
1808.9581 1808.9512 -0.0069 -4 205 219 HSQFIGYPITLYLEK
1847.797 1847.8038 0.0068 4 292 306 NPDDITQEEYGEFYK
1911.0446 1911.0476 0.003 2 624 639 KHLEINPDHPIVETLR
1911.0446 1911.0476 0.003 2 624 639 KHLEINPDHPIVETLR
2015.0443 2015.0425 -0.0018 -1 181 196 VILHLKEDQTEYLEER
2015.0443 2015.0425 -0.0018 -1 181 196 VILHLKEDQTEYLEER
2034.0654 2034.0372 -0.0282 -14 276 291 YIDQEELNKTKPIWTR
2059.0051 2059.009 0.0039 2 412 428 CLELFSELAEDKENYKK
2171.1455 2171.155 0.0095 4 181 197 VILHLKEDQTEYLEERR
2176.9451 2176.9622 0.0171 8 457 475 YHTSQSGDEMTSLSEYV
SR
2176.9451 2176.9622 0.0171 8 457 475 YHTSQSGDEMTSLSEYV
SR
2255.9587 2255.97 0.0113 5 149 168 HNDDEQYAWESSAGGS
FTVR
2255.9587 2255.97 0.0113 5 149 168 HNDDEQYAWESSAGGS
FTVR
2317.1243 2317.1086 -0.0157 -7 360 378 VFIMDSCDELIPEYLNFIR
2358.1968 2358.1667 -0.0301 -13 379 399 GVVDSEDLPLNISREMLQ
QSK
2369.1882 2369.1697 -0.0185 -8 429 448 FYEAFSKNLKLGIHEDST
NR
2391.1826 2391.1763 -0.0063 -3 482 502 SIYYITGESKEQVANSAF
VER
2988.5312 2988.5474 0.0162 5 653 679 DLVVLLFETALLSSGFSLE
DPQTHSNR
6 DEAD (Asp-Glu-Ala-Asp) box polypeptide 1 [Homo gi|4826686 82379.8 87 99.999 1 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
901.5253 901.524 -0.0013 -1 455 461 LWERLGK
975.5006 975.4911 -0.0095 -10 452 458 TDRLWER
1048.6149 1048.6185 0.0036 3 491 499 ILKGEYAVR
1111.6832 1111.6936 0.0104 9 320 330 ELLIIGGVAAR
1111.6832 1111.6936 0.0104 9 320 330 ELLIIGGVAAR 1 0
1380.8684 1380.8829 0.0145 11 318 330 LRELLIIGGVAAR
1386.7239 1386.7163 -0.0076 -5 422 432 IMHFPTWVDLK
1467.7664 1467.7673 0.0009 1 211 223 DLGLAFEIPPHMK
1610.8068 1610.8152 0.0084 5 387 400 MHNQIPQVTSDGKR
1663.8948 1663.8977 0.0029 2 563 577 KGDVRFLICTDVAAR
1759.941 1759.9385 -0.0025 -1 401 416 LQVIVCSATLHSFDVK
1766.9258 1766.9109 -0.0149 -8 208 223 NGKDLGLAFEIPPHMK
1968.0396 1968.0535 0.0139 7 331 349 DQLSVLENGVDIVVGTPG
R
1968.0396 1968.0535 0.0139 7 331 349 DQLSVLENGVDIVVGTPG
R
1972.0724 1972.047 -0.0254 -13 417 432 KLSEKIMHFPTWVDLK
2002.9287 2002.9343 0.0056 3 473 490 DNTRPGANSPEMWSEAI
K
2002.9287 2002.9343 0.0056 3 473 490 DNTRPGANSPEMWSEAI
K
2079.1121 2079.095 -0.0171 -8 578 596 GIDIHGVPYVINVTLPDEK
2134.1079 2134.1172 0.0093 4 721 738 EAQTSFLHLGYLPNQLFR
2134.1079 2134.1172 0.0093 4 721 738 EAQTSFLHLGYLPNQLFR
2138.1814 2138.1819 0.0005 0 289 307 ALIVEPSRELAEQTLNNIK
2372.1768 2372.179 0.0022 1 366 386 FLVLDEADGLLSQGYSDF
INR
2372.1768 2372.179 0.0022 1 366 386 FLVLDEADGLLSQGYSDF
INR
2564.3606 2564.3567 -0.0039 -2 53 75 TGAFSIPVIQIVYETLKDQ
QEGK
2876.5051 2876.5066 0.0015 1 578 602 GIDIHGVPYVINVTLPDEK
QNYVHR
2896.5261 2896.5046 -0.0215 -7 331 358 DQLSVLENGVDIVVGTPG
RLDDLVSTGK
Spot Idx/Pos 167/G14 23 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 crystallin, zeta variant [Homo sapiens] gi|62089008 35384.7 83 99.996 10 70.02
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1054.564 1054.5559 -0.0081 -8 235 244 DLSLLSHGGR
1221.6512 1221.6334 -0.0178 -15 15 25 VFEFGGPEVLK
1221.6512 1221.6334 -0.0178 -15 15 25 VFEFGGPEVLK
1249.6755 1249.6769 0.0014 1 1 11 ITMATGQKLMR
1527.7954 1527.7863 -0.0091 -6 127 140 QGAAIGIPYFTAYR
1527.7954 1527.7863 -0.0091 -6 127 140 QGAAIGIPYFTAYR 10 70.02
1557.7842 1557.7848 0.0006 0 44 57 VHACGVNPVETYIR
1633.8557 1633.8478 -0.0079 -5 190 203 IVLQNGAHEVFNHR
1633.8557 1633.8478 -0.0079 -5 190 203 IVLQNGAHEVFNHR
1773.0269 1773.0081 -0.0188 -11 28 43 SDIAVPIPKDHQVLIK
2123.1025 2123.1028 0.0003 0 150 172 AGESVLVHGASGGVGLA
ACQIAR
2123.1025 2123.1028 0.0003 0 150 172 AGESVLVHGASGGVGLA
ACQIAR
2391.26 2391.2693 0.0093 4 37 57 DHQVLIKVHACGVNPVET
YIR
2551.2351 2551.2666 0.0315 12 95 118 VFTSSTISGGYAEYALAA
DHTVYK
2716.4192 2716.4446 0.0254 9 64 90 KPLLPYTPGSDVAGVIEA
VGDNASAFK
2804.4436 2804.4668 0.0232 8 178 203 VLGTAGTEEGQKIVLQNG
AHEVFNHR
2844.5142 2844.4875 -0.0267 -9 64 91 KPLLPYTPGSDVAGVIEA
VGDNASAFKK
2 mitochondrial malate dehydrogenase 2, NAD [Homo gi|89574129 31948.8 77 99.986 20 97.029
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1147.6581 1147.6473 -0.0108 -9 171 182 VNVPVIGGHAGK
1233.7201 1233.7104 -0.0097 -8 145 155 IFGVTTLDIVR
1233.7201 1233.7104 -0.0097 -8 145 155 IFGVTTLDIVR 14 87.003
1281.6982 1281.6901 -0.0081 -6 71 83 GCDVVVIPAGVPR
1454.7056 1454.6948 -0.0108 -7 221 236 AGAGSATLSMAYAGAR
1454.7056 1454.6948 -0.0108 -7 221 236 AGAGSATLSMAYAGAR
1560.8016 1560.7906 -0.011 -7 195 208 VDFPQDQLTALTGR 6 30.843
1560.8016 1560.7906 -0.011 -7 195 208 VDFPQDQLTALTGR
1793.0894 1793.0842 -0.0052 -3 6 24 VAVLGASGGIGQPLSLLL
K
1916.9309 1916.9399 0.009 5 259 275 SQETECTYFSTPLLLGK
2143.1658 2143.1716 0.0058 3 137 155 HGVYNPNKIFGVTTLDIV
R
2143.1658 2143.1716 0.0058 3 137 155 HGVYNPNKIFGVTTLDIV
R
2365.2397 2365.2437 0.004 2 32 53 LTLYDIAHTPGVAADLSHI
ETK
2365.2397 2365.2437 0.004 2 32 53 LTLYDIAHTPGVAADLSHI
ETK
2695.3945 2695.4033 0.0088 3 58 83 GYLGPEQLPDCLKGCDV
VVIPAGVPR
2855.5334 2855.554 0.0206 7 183 208 TIIPLISQCTPKVDFPQDQ
LTALTGR
7 glyceraldehyde-3-phosphate dehydrogenase [Homo gi|31645 36031.4 72 99.957
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1330.6493 1330.6451 -0.0042 -3 324 335 VVDLMAHMASKE
1473.7729 1473.7878 0.0149 10 235 248 VPTANVSVVDLTCR
1613.9009 1613.8972 -0.0037 -2 67 80 LVINGNPITIFQER
1613.9009 1613.8972 -0.0037 -2 67 80 LVINGNPITIFQER
1646.8933 1646.8862 -0.0071 -4 220 234 VIPELDGKLTGMAFR
1763.8022 1763.7977 -0.0045 -3 310 323 LISWYDNEFGYSNR
1763.8022 1763.7977 -0.0045 -3 310 323 LISWYDNEFGYSNR
2041.1075 2041.1089 0.0014 1 67 84 LVINGNPITIFQERDPSK
2041.1075 2041.1089 0.0014 1 67 84 LVINGNPITIFQERDPSK
2113.1399 2113.1384 -0.0015 -1 62 80 AENGKLVINGNPITIFQER
2277.0378 2277.0623 0.0245 11 87 107 WGDAGAEYVVESTGVFT
TMEK
2369.2104 2369.2415 0.0311 13 118 139 RVIISAPSADAPMFVMGV
NHEK
2518.2168 2518.2429 0.0261 10 85 107 IKWGDAGAEYVVESTGV
FTTMEK
2540.3467 2540.3274 -0.0193 -8 62 84 AENGKLVINGNPITIFQER
DPSK
2595.3599 2595.3623 0.0024 1 163 186 VIHDNFGIVEGLMTTVHAI
TATQK
2933.4534 2933.4802 0.0268 9 119 145 VIISAPSADAPMFVMGVN
HEKYDNSLK
12 uracil DNA glycosylase [Homo sapiens] gi|35053 35470.1 57 98.784
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1473.7729 1473.7878 0.0149 10 234 247 VPTANVSVVDLTCR
1613.9009 1613.8972 -0.0037 -2 67 80 LVINGNPITIFQER
1613.9009 1613.8972 -0.0037 -2 67 80 LVINGNPITIFQER
1763.8022 1763.7977 -0.0045 -3 309 322 LISWYDNEFGYSNR
1763.8022 1763.7977 -0.0045 -3 309 322 LISWYDNEFGYSNR
2041.1075 2041.1089 0.0014 1 67 84 LVINGNPITIFQERDPSK
2041.1075 2041.1089 0.0014 1 67 84 LVINGNPITIFQERDPSK
2113.1399 2113.1384 -0.0015 -1 62 80 AENGKLVINGNPITIFQER
2277.0378 2277.0623 0.0245 11 87 107 WGDAGAEYVVESTGVFT
TMEK
2369.2104 2369.2415 0.0311 13 118 139 RVIISAPSADAPMFVMGV
NHEK
2518.2168 2518.2429 0.0261 10 85 107 IKWGDAGAEYVVESTGV
FTTMEK
2540.3467 2540.3274 -0.0193 -8 62 84 AENGKLVINGNPITIFQER
DPSK
2595.3599 2595.3623 0.0024 1 163 186 VIHDNFGIVEGLMTTVHAI
TATQK
2933.4534 2933.4802 0.0268 9 119 145 VIISAPSADAPMFVMGVN
HEKYDNSLK
Spot Idx/Pos 168/G16 24 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 glyceraldehyde-3-phosphate dehydrogenase [Homo gi|89573929 24604.7 107 100 2 0
sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1473.7729 1473.845 0.0721 49 210 223 VPTANVSVVDLTCR
1613.9009 1613.9684 0.0675 42 42 55 LVINGNPITIFQER
1613.9009 1613.9684 0.0675 42 42 55 LVINGNPITIFQER 2 0
1645.9093 1645.9619 0.0526 32 195 209 VIPELNGKLTGMAFR
2041.1075 2041.1807 0.0732 36 42 59 LVINGNPITIFQERDPSK
2041.1075 2041.1807 0.0732 36 42 59 LVINGNPITIFQERDPSK
2113.1399 2113.2173 0.0774 37 37 55 AENGKLVINGNPITIFQER
2213.1091 2213.1819 0.0728 33 94 114 VIISAPSADAPMFVMGVN
HEK
2213.1091 2213.1819 0.0728 33 94 114 VIISAPSADAPMFVMGVN
HEK
2277.0378 2277.1165 0.0787 35 62 82 WGDAGAEYVVESTGVFT
TMEK
2369.2104 2369.3091 0.0987 42 93 114 RVIISAPSADAPMFVMGV
NHEK
2518.2168 2518.3201 0.1033 41 60 82 IKWGDAGAEYVVESTGV
FTTMEK
2540.3467 2540.3562 0.0095 4 37 59 AENGKLVINGNPITIFQER
DPSK
2595.3599 2595.4463 0.0864 33 138 161 VIHDNFGIVEGLMTTVHAI
TATQK
2595.3599 2595.4463 0.0864 33 138 161 VIHDNFGIVEGLMTTVHAI
TATQK
2617.5034 2617.417 -0.0864 -33 176 202 GALQNIIPASTGAAKAVG
KVIPELNGK
2933.4534 2933.5596 0.1062 36 94 120 VIISAPSADAPMFVMGVN
HEKYDNSLK
3308.5642 3308.6765 0.1123 34 3 30 VDIVAINDPFIDLNYMVYM
FQYDSTHGK
10 MDH2 [Homo sapiens] gi|49168580 35536.8 70 99.935 16 78.164
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1221.6837 1221.6976 0.0139 11 325 335 ASIKKGEDFVK
1233.7201 1233.7793 0.0592 48 166 176 IFGVTTLDIVR
1233.7201 1233.7793 0.0592 48 166 176 IFGVTTLDIVR 16 78.164
1281.6982 1281.7611 0.0629 49 92 104 GCDVVVIPAGVPR
1327.6714 1327.7172 0.0458 34 258 269 FVFSLVDAMNGK
1352.8372 1352.7809 -0.0563 -42 2 14 LSALVRPVSAALR
1454.7056 1454.7694 0.0638 44 242 257 AGAGSATLSMAYAGAR
1515.8451 1515.8148 -0.0303 -20 315 328 MISDAIPELKASIK
1560.8016 1560.8658 0.0642 41 216 229 VDFPQDQLTALTGR
1560.8016 1560.8658 0.0642 41 216 229 VDFPQDQLTALTGR
1601.8645 1601.8942 0.0297 19 177 191 ANTFVAELKGLDPAR
1793.0894 1793.1414 0.052 29 27 45 VAVLGASGGIGQPLSLLL
K
2143.1658 2143.2273 0.0615 29 158 176 HGVYNPNKIFGVTTLDIV
R
2365.2397 2365.3191 0.0794 34 53 74 LTLYDIAHTPGVAADLSHI
ETK
2365.2397 2365.3191 0.0794 34 53 74 LTLYDIAHTPGVAADLSHI
ETK
4 uracil DNA glycosylase [Homo sapiens] gi|35053 35470.1 52 96.065
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1645.9093 1645.9619 0.0526 32 219 233 VIPELNGKLTGMAFR
1763.8022 1763.8685 0.0663 38 309 322 LISWYDNEFGYSNR
1763.8022 1763.8685 0.0663 38 309 322 LISWYDNEFGYSNR
2041.1075 2041.1807 0.0732 36 67 84 LVINGNPITIFQERDPSK
2041.1075 2041.1807 0.0732 36 67 84 LVINGNPITIFQERDPSK
2113.1399 2113.2173 0.0774 37 62 80 AENGKLVINGNPITIFQER
2213.1091 2213.1819 0.0728 33 119 139 VIISAPSADAPMFVMGVN
HEK
2213.1091 2213.1819 0.0728 33 119 139 VIISAPSADAPMFVMGVN
HEK
2277.0378 2277.1165 0.0787 35 87 107 WGDAGAEYVVESTGVFT
TMEK
2540.3467 2540.3562 0.0095 4 62 84 AENGKLVINGNPITIFQER
DPSK
2595.3599 2595.4463 0.0864 33 163 186 VIHDNFGIVEGLMTTVHAI
TATQK
2595.3599 2595.4463 0.0864 33 163 186 VIHDNFGIVEGLMTTVHAI
TATQK
2933.4534 2933.5596 0.1062 36 119 145 VIISAPSADAPMFVMGVN
HEKYDNSLK
3308.5642 3308.6765 0.1123 34 28 55 VDIVAINDPFIDLNYMVYM
FQYDSTHGK
Spot Idx/Pos 169/G18 25 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 172 100 14 88.077
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
977.5964 977.5933 -0.0031 -3 150 157 LVAMKFLR
984.6199 984.6278 0.0079 8 134 142 GLVGEIIKR
984.6199 984.6278 0.0079 8 19 27 GLVGEIIKR
1069.5636 1069.5635 -0.0001 0 230 239 NIIHGSDSVK
1175.6571 1175.6639 0.0068 6 172 181 DRPFFPGLVK
1175.6571 1175.6639 0.0068 6 172 181 DRPFFPGLVK
1344.7633 1344.7697 0.0064 5 122 133 TFIAIKPDGVQR
1344.7633 1344.7697 0.0064 5 7 18 TFIAIKPDGVQR 15 90.107
1516.8845 1516.8929 0.0084 6 19 31 GLVGEIIKRFEQK
1516.8845 1516.8929 0.0084 6 134 146 GLVGEIIKRFEQK
1710.8809 1710.8773 -0.0036 -2 158 171 ASEEHLKQHYIDLK
1785.9163 1785.9221 0.0058 3 204 220 VMLGETNPADSKPGTIR
1785.9163 1785.9221 0.0058 3 89 105 VMLGETNPADSKPGTIR
1895.9789 1895.9728 -0.0061 -3 244 258 EISLWFKPEELVDYK
2073.1279 2073.1257 -0.0022 -1 165 181 QHYIDLKDRPFFPGLVK
2073.1279 2073.1257 -0.0022 -1 165 181 QHYIDLKDRPFFPGLVK
2093.0557 2093.0549 -0.0008 0 182 200 YMNSGPVVAMVWEGLN
VVK
2311.1855 2311.1824 -0.0031 -1 240 258 SAEKEISLWFKPEELVDY
K
2311.1855 2311.1824 -0.0031 -1 240 258 SAEKEISLWFKPEELVDY
K
2407.2261 2407.2288 0.0027 1 182 203 YMNSGPVVAMVWEGLN
VVKTGR
2867.5203 2867.5078 -0.0125 -4 158 181 ASEEHLKQHYIDLKDRPF
FPGLVK
2867.5203 2867.5078 -0.0125 -4 158 181 ASEEHLKQHYIDLKDRPF
FPGLVK
3361.7312 3361.741 0.0098 3 230 258 NIIHGSDSVKSAEKEISLW
FKPEELVDYK
4 Putative nucleoside diphosphate kinase (NDK) (NDP gi|3914116 15519 51 95.159
kinase)
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1069.5636 1069.5635 -0.0001 0 100 109 NIIHGSDSVK
1175.6571 1175.6639 0.0068 6 42 51 DRPFFPGLVK
1175.6571 1175.6639 0.0068 6 42 51 DRPFFPGLVK
1785.9163 1785.9221 0.0058 3 74 90 VMLGETNPADSKPGTIR
1785.9163 1785.9221 0.0058 3 74 90 VMLGETNPADSKPGTIR
2073.1279 2073.1257 -0.0022 -1 35 51 QHYIDLKDRPFFPGLVK
2073.1313 2073.1257 -0.0056 -3 17 34 GFRLVAMKFLPASEEHLK
2093.0557 2093.0549 -0.0008 0 52 70 YMNSGPVVAMVWEGLN
VVK
2407.2261 2407.2288 0.0027 1 52 73 YMNSGPVVAMVWEGLN
VVKTGR
Spot Idx/Pos 170/G20 26 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 163 100 29 99.785
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
911.4733 911.4702 -0.0031 -3 143 149 FEQKGFR
984.6199 984.6236 0.0037 4 19 27 GLVGEIIKR 6 52.426
984.6199 984.6236 0.0037 4 134 142 GLVGEIIKR
994.4774 994.4841 0.0067 7 221 229 GDFCIQVGR
994.4774 994.4841 0.0067 7 106 114 GDFCIQVGR 9 76.913
1069.5636 1069.5569 -0.0067 -6 230 239 NIIHGSDSVK
1175.6571 1175.6576 0.0005 0 172 181 DRPFFPGLVK
1175.6571 1175.6576 0.0005 0 172 181 DRPFFPGLVK
1344.7633 1344.764 0.0007 1 122 133 TFIAIKPDGVQR
1344.7633 1344.764 0.0007 1 7 18 TFIAIKPDGVQR 17 96.204
1516.8845 1516.88 -0.0045 -3 134 146 GLVGEIIKRFEQK
1710.8809 1710.8801 -0.0008 0 158 171 ASEEHLKQHYIDLK
1785.9163 1785.9178 0.0015 1 89 105 VMLGETNPADSKPGTIR
1785.9163 1785.9178 0.0015 1 204 220 VMLGETNPADSKPGTIR
1895.9789 1895.9713 -0.0076 -4 244 258 EISLWFKPEELVDYK
2073.1279 2073.1345 0.0066 3 165 181 QHYIDLKDRPFFPGLVK
2093.0557 2093.0532 -0.0025 -1 182 200 YMNSGPVVAMVWEGLN
VVK
2311.1855 2311.1882 0.0027 1 240 258 SAEKEISLWFKPEELVDY
K
2761.376 2761.376 0 0 204 229 VMLGETNPADSKPGTIR
GDFCIQVGR
2867.5203 2867.4978 -0.0225 -8 158 181 ASEEHLKQHYIDLKDRPF
FPGLVK
7 Putative nucleoside diphosphate kinase (NDK) (NDP gi|3914116 15519 63 99.649 9 76.913
kinase)
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
911.4733 911.4702 -0.0031 -3 13 19 FEQKGFR
994.4774 994.4841 0.0067 7 91 99 GDFCIQVGR
994.4774 994.4841 0.0067 7 91 99 GDFCIQVGR 9 76.913
1069.5636 1069.5569 -0.0067 -6 100 109 NIIHGSDSVK
1175.6571 1175.6576 0.0005 0 42 51 DRPFFPGLVK
1175.6571 1175.6576 0.0005 0 42 51 DRPFFPGLVK
1785.9163 1785.9178 0.0015 1 74 90 VMLGETNPADSKPGTIR
1785.9163 1785.9178 0.0015 1 74 90 VMLGETNPADSKPGTIR
2073.1313 2073.1345 0.0032 2 17 34 GFRLVAMKFLPASEEHLK
2093.0557 2093.0532 -0.0025 -1 52 70 YMNSGPVVAMVWEGLN
VVK
2761.376 2761.376 0 0 74 99 VMLGETNPADSKPGTIR
GDFCIQVGR
8 RNA binding motif protein 3 isoform a [Homo sapiens] gi|5803137 17160 41 41.804
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
867.4067 867.4026 -0.0041 -5 132 138 SRDYNGR
1437.5665 1437.5724 0.0059 4 146 157 YSGGNYRDNYDN
1437.5665 1437.5724 0.0059 4 146 157 YSGGNYRDNYDN
1606.6992 1606.7145 0.0153 10 139 152 NQGGYDRYSGGNYR
1730.7556 1730.754 -0.0016 -1 117 131 YYDSRPGGYGYGYGR
1730.7556 1730.754 -0.0016 -1 117 131 YYDSRPGGYGYGYGR
1981.9589 1981.9657 0.0068 3 48 65 GFGFITFTNPEHASVAMR
1981.9589 1981.9657 0.0068 3 48 65 GFGFITFTNPEHASVAMR
2225.092 2225.1077 0.0157 7 46 65 SRGFGFITFTNPEHASVA
MR
2227.9023 2227.9102 0.0079 4 139 157 NQGGYDRYSGGNYRDN
YDN
2227.9023 2227.9102 0.0079 4 139 157 NQGGYDRYSGGNYRDN
YDN
Spot Idx/Pos 171/G22 27 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 type 1 RNA helicase pNORF1 gi|1885356 122976 202 100 1 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
942.5843 942.5868 0.0025 3 858 865 RLNVALTR
952.5502 952.5402 -0.01 -10 342 349 IAYFTLPK
1099.5742 1099.5775 0.0033 3 245 253 IPSEQEQLR
1107.5792 1107.5828 0.0036 3 678 687 AGLSQSLFER
1129.6476 1129.64 -0.0076 -7 333 341 WDLGLNKKR
1135.7673 1135.7693 0.002 2 688 697 LVVLGIRPIR
1135.7673 1135.7693 0.002 2 688 697 LVVLGIRPIR
1182.6953 1182.6874 -0.0079 -7 918 928 KLVNTINPGAR
1182.6953 1182.6874 -0.0079 -7 918 928 KLVNTINPGAR
1206.5282 1206.5366 0.0084 7 929 938 FMTTAMYDAR
1206.5282 1206.5366 0.0084 7 929 938 FMTTAMYDAR 1 0
1219.6317 1219.6475 0.0158 13 939 949 EAIIPGSVYDR
1219.6317 1219.6475 0.0158 13 939 949 EAIIPGSVYDR
1222.6249 1222.6318 0.0069 6 908 917 ESLMQFSKPR
1286.7578 1286.7528 -0.005 -4 866 877 ARYGVIIVGNPK
1286.7578 1286.7528 -0.005 -4 866 877 ARYGVIIVGNPK
1322.7136 1322.7274 0.0138 10 833 843 EKDFIILSCVR
1380.6542 1380.6582 0.004 3 1106 1118 AYQHGGVTGLSQY
1431.7954 1431.8054 0.01 7 499 511 TVTSATIVYHLAR
1431.7954 1431.8054 0.01 7 499 511 TVTSATIVYHLAR
1490.7822 1490.7893 0.0071 5 149 162 GNTSGSHIVNHLVR
1490.7822 1490.7893 0.0071 5 149 162 GNTSGSHIVNHLVR
1531.8074 1531.809 0.0016 1 320 332 LKESQTQDNITVR
1567.7611 1567.761 -0.0001 0 844 857 ANEHQGIGFLNDPR
1567.7611 1567.761 -0.0001 0 844 857 ANEHQGIGFLNDPR
1603.7961 1603.8101 0.014 9 383 396 VPDNYGDEIAIELR
1657.8254 1657.8335 0.0081 5 342 355 IAYFTLPKTDSDMR
1723.8622 1723.8701 0.0079 5 844 858 ANEHQGIGFLNDPRR
1816.8751 1816.8944 0.0193 11 429 444 TFAVDETSVSGYIYHK
1824.9126 1824.9191 0.0065 4 817 832 LYQEVEIASVDAFQGR
1824.9126 1824.9191 0.0065 4 817 832 LYQEVEIASVDAFQGR
1862.0857 1862.0919 0.0062 3 481 498 TVLQRPLSLIQGPPGTGK
1862.0857 1862.0919 0.0062 3 481 498 TVLQRPLSLIQGPPGTGK
1896.8933 1896.9064 0.0131 7 1089 1105 SQIDVALSQDSTYQGER
1910.0129 1910.0242 0.0113 6 550 566 EAIDSPVSFLALHNQIR
1910.0129 1910.0242 0.0113 6 550 566 EAIDSPVSFLALHNQIR
1914.0078 1914.0186 0.0108 6 783 800 AGAKPDQIGIITPYEGQR
1947.9486 1947.9583 0.0097 5 296 311 YEDAYQYQNIFGPLVK
1953.0118 1953.0227 0.0109 6 656 673 QLILVGDHCQLGPVVMC
K
1988.0236 1988.0309 0.0073 4 463 480 FTAQGLPDLNHSQVYAV
K
2000.946 2000.9686 0.0226 11 221 236 DINWDSSQWQPLIQDR
2047.0302 2047.0461 0.0159 8 577 594 LQQLKDETGELSSADEK
R
2082.05 2082.0237 -0.0263 -13 817 834 LYQEVEIASVDAFQGREK
2144.1245 2144.1235 -0.001 0 462 480 RFTAQGLPDLNHSQVYA
VK
2246.124 2246.1479 0.0239 11 397 416 SSVGAPVEVTHNFQVDF
VWK
2253.1543 2253.1572 0.0029 1 512 533 QGNGPVLVCAPSNIAVD
QLTEK
2308.2295 2308.2256 -0.0039 -2 376 396 GIGHVIKVPDNYGDEIAIE
LR
2530.2778 2530.3091 0.0313 12 632 655 SILIDESTQATEPECMVP
VVLGAK
2538.1406 2538.157 0.0164 6 96 116 TSQLLAELNFEEDEEDTY
YTK
2815.4106 2815.4187 0.0081 3 271 295 ENPSATLEDLEKPGVDEE
PQHVLLR
31 transcription activator gi|292496 114659.1 22 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1094.6027 1094.597 -0.0057 -5 427 435 VLIFSQMTR
1115.5844 1115.6006 0.0162 15 229 237 YLVIDEAHR
1159.6371 1159.646 0.0089 8 865 873 YKAPFHQLR
1159.6371 1159.646 0.0089 8 865 873 YKAPFHQLR
1174.6327 1174.6414 0.0087 7 102 111 GGPLRDYQIR
1222.6248 1222.6318 0.007 6 182 192 VICFVGDKDAR
1237.6575 1237.6388 -0.0187 -15 467 476 FLEVEFLGQR
1305.6909 1305.7035 0.0126 10 740 751 NPDIPNPALAQR
1308.6946 1308.6876 -0.007 -5 774 784 LLTQGFTNWTK
1397.8223 1397.8152 -0.0071 -5 562 573 LRLDSIVIQQGR
1619.7964 1619.8162 0.0198 12 705 717 QPNVQDFQFFPPR
1645.8809 1645.87 -0.0109 -7 867 880 APFHQLRIQYGTSK
1670.9119 1670.9052 -0.0067 -4 837 850 IMAQIERGEARIQR
1686.902 1686.8951 -0.0069 -4 544 557 LITDNTVEERIVER
1819.9297 1819.9084 -0.0213 -12 740 755 NPDIPNPALAQREEQK
43 Tax1-binding protein 2 [Homo sapiens] gi|76560593 148167.9 21 0
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1159.6317 1159.646 0.0143 12 245 255 ETLTGELAGLR
1159.6317 1159.646 0.0143 12 245 255 ETLTGELAGLR
1190.6375 1190.6339 -0.0036 -3 411 421 STVNALTSELR
1320.6212 1320.637 0.0158 12 453 463 DSCLREAEELR
1333.6957 1333.6971 0.0014 1 945 956 EVLDASESRTVK
1407.7703 1407.7583 -0.012 -9 682 693 QQLDHARGLELK
1486.772 1486.7902 0.0182 12 487 498 LRESQEGREVQR
1540.7754 1540.7549 -0.0205 -13 1299 1313 RSSAPFSPPSGPPEK
1584.8088 1584.8094 0.0006 0 1195 1208 SHEDTVRLSAEKGR
1669.9119 1669.8969 -0.015 -9 56 69 LDLNRLVAQLEEEK
1670.9071 1670.9052 -0.0019 -1 61 75 LVAQLEEEKSALQGR
1747.9224 1747.9001 -0.0223 -13 207 221 LEKEALEGSLFEVQR
1947.9552 1947.9583 0.0031 2 833 849 TQTSALNRQLAEMEAER
2000.9744 2000.9686 -0.0058 -3 489 505 ESQEGREVQRQEAGELR
2284.1638 2284.176 0.0122 5 1124 1143 QRQEGEAAALNTVQKLQ
DER
2287.2039 2287.1743 -0.0296 -13 210 229 EALEGSLFEVQRQLAQLE
AR
Spot Idx/Pos 172/G24 28 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 Regulator of nonsense transcripts 1 (ATP-dependent gi|17380291 124266.7 216 100
helicase RENT1) (Nonsense mRNA reducing factor 1
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
942.5843 942.5738 -0.0105 -11 869 876 RLNVALTR
952.5502 952.5398 -0.0104 -11 342 349 IAYFTLPK
1059.6196 1059.6069 -0.0127 -12 879 888 YGVIIVGNPK
1099.5742 1099.5876 0.0134 12 245 253 IPSEQEQLR
1107.5792 1107.5837 0.0045 4 689 698 AGLSQSLFER
1135.7673 1135.7666 -0.0007 -1 699 708 LVVLGIRPIR
1135.7673 1135.7666 -0.0007 -1 699 708 LVVLGIRPIR
1182.6953 1182.7019 0.0066 6 929 939 KLVNTINPGAR
1206.5282 1206.5421 0.0139 12 940 949 FMTTAMYDAR
1206.5282 1206.5421 0.0139 12 940 949 FMTTAMYDAR
1218.7244 1218.7244 0 0 190 200 NVFLLGFIPAK
1222.6249 1222.6359 0.011 9 919 928 ESLMQFSKPR
1223.7106 1223.699 -0.0116 -9 908 918 VLVEGPLNNLR
1223.7106 1223.699 -0.0116 -9 908 918 VLVEGPLNNLR
1286.7578 1286.7611 0.0033 3 877 888 ARYGVIIVGNPK
1286.7578 1286.7611 0.0033 3 877 888 ARYGVIIVGNPK
1364.7783 1364.7693 -0.009 -7 456 467 LLGHEVEDVIIK
1380.6542 1380.671 0.0168 12 1117 1129 AYQHGGVTGLSQY
1431.7954 1431.8002 0.0048 3 510 522 TVTSATIVYHLAR
1431.7954 1431.8002 0.0048 3 510 522 TVTSATIVYHLAR
1490.7822 1490.7894 0.0072 5 149 162 GNTSGSHIVNHLVR
1490.7822 1490.7894 0.0072 5 149 162 GNTSGSHIVNHLVR
1567.7611 1567.7598 -0.0013 -1 855 868 ANEHQGIGFLNDPR
1567.7611 1567.7598 -0.0013 -1 855 868 ANEHQGIGFLNDPR
1588.827 1588.8282 0.0012 1 893 904 QPLWNHLLNYYK
1603.7961 1603.7972 0.0011 1 394 407 VPDNYGDEIAIELR
1630.8435 1630.8455 0.002 1 350 363 TDSGNEDLVIIWLR
1723.8622 1723.861 -0.0012 -1 855 869 ANEHQGIGFLNDPRR
1723.8622 1723.861 -0.0012 -1 855 869 ANEHQGIGFLNDPRR
1816.8751 1816.8787 0.0036 2 440 455 TFAVDETSVSGYIYHK
1824.9126 1824.9178 0.0052 3 828 843 LYQEVEIASVDAFQGR
1824.9126 1824.9178 0.0052 3 828 843 LYQEVEIASVDAFQGR
1862.0857 1862.0867 0.001 1 492 509 TVLQRPLSLIQGPPGTGK
1862.0857 1862.0867 0.001 1 492 509 TVLQRPLSLIQGPPGTGK
1888.9261 1888.934 0.0079 4 812 827 SYLVQYMQFSGSLHTK
1910.0129 1910.0179 0.005 3 561 577 EAIDSPVSFLALHNQIR
1910.0129 1910.0179 0.005 3 561 577 EAIDSPVSFLALHNQIR
1914.0078 1914.0145 0.0067 4 794 811 AGAKPDQIGIITPYEGQR
1947.9486 1947.9462 -0.0024 -1 296 311 YEDAYQYQNIFGPLVK
1988.0236 1988.0115 -0.0121 -6 474 491 FTAQGLPDLNHSQVYAV
K
2000.946 2000.9602 0.0142 7 221 236 DINWDSSQWQPLIQDR
2047.0302 2047.033 0.0028 1 588 605 LQQLKDETGELSSADEK
R
2144.1245 2144.1265 0.002 1 473 491 RFTAQGLPDLNHSQVYA
VK
2153.146 2153.1426 -0.0034 -2 559 577 SREAIDSPVSFLALHNQIR
2308.2295 2308.23 0.0005 0 387 407 GIGHVIKVPDNYGDEIAIE
LR
2308.2295 2308.23 0.0005 0 387 407 GIGHVIKVPDNYGDEIAIE
LR
2538.1406 2538.147 0.0064 3 96 116 TSQLLAELNFEEDEEDTY
YTK
2815.4106 2815.4021 -0.0085 -3 271 295 ENPSATLEDLEKPGVDEE
PQHVLLR
2893.3936 2893.3936 0 0 715 741 MHPALSAFPSNIFYEGSL
QNGVTAADR
Spot Idx/Pos 187/H2 29 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 glutamate dehydrogenase 1 variant [Homo sapiens] gi|62897195 61301.2 107 100 13 86.964
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
956.52 956.5281 0.0081 8 454 460 LTFKYER
956.52 956.5281 0.0081 8 454 460 LTFKYER
963.5258 963.5309 0.0051 5 528 535 YNLGLDLR
995.5342 995.5436 0.0094 9 204 211 RFTMELAK
1000.4556 1000.4669 0.0113 11 69 76 MVEGFFDR
1000.4556 1000.4669 0.0113 11 69 76 MVEGFFDR
1059.533 1059.5468 0.0138 13 445 453 NLNHVSYGR
1059.533 1059.5468 0.0138 13 445 453 NLNHVSYGR
1394.746 1394.748 0.002 1 524 535 TAMKYNLGLDLR
1425.6281 1425.6279 -0.0002 0 125 136 DDGSWEVIEGYR
1425.6281 1425.6279 -0.0002 0 125 136 DDGSWEVIEGYR 1 0
1488.828 1488.8413 0.0133 9 35 50 GQPAAAPQPGLALAAR
1491.726 1491.7263 0.0003 0 504 516 DIVHSGLAYTMER
1543.8325 1543.8275 -0.005 -3 77 90 GASIVEDKLVEDLR
1543.8325 1543.8275 -0.005 -3 77 90 GASIVEDKLVEDLR 12 81.881
1581.7291 1581.7305 0.0014 1 124 136 RDDGSWEVIEGYR
1737.8918 1737.8822 -0.0096 -6 481 496 HGGTIPIVPTAEFQDR
1737.8918 1737.8822 -0.0096 -6 481 496 HGGTIPIVPTAEFQDR
1748.89 1748.8826 -0.0074 -4 303 318 TFVVQGFGNVGLHSMR
1748.89 1748.8826 -0.0074 -4 303 318 TFVVQGFGNVGLHSMR
1837.0516 1837.0535 0.0019 1 108 123 IIKPCNHVLSLSFPIR
1837.0516 1837.0535 0.0019 1 108 123 IIKPCNHVLSLSFPIR
1915.9218 1915.9131 -0.0087 -5 213 231 GFIGPGIDVPAPDMSTGE
R
1920.912 1920.9061 -0.0059 -3 461 476 DSNYHLLMSVQESLER
1920.912 1920.9061 -0.0059 -3 461 476 DSNYHLLMSVQESLER
1958.0381 1958.0212 -0.0169 -9 347 363 ELEDFKLQHGSILGFPK
1993.1527 1993.1251 -0.0276 -14 108 124 IIKPCNHVLSLSFPIRR
2044.0167 2044.0094 -0.0073 -4 212 231 KGFIGPGIDVPAPDMSTG
ER
2049.0068 2049.0005 -0.0063 -3 461 477 DSNYHLLMSVQESLERK
2164.0703 2164.0613 -0.009 -4 497 516 ISGASEKDIVHSGLAYTM
ER
2164.0703 2164.0613 -0.009 -4 497 516 ISGASEKDIVHSGLAYTM
ER
2242.1714 2242.1565 -0.0149 -7 400 420 IIAEGANGPTTPEADKIFL
ER
2242.1714 2242.1565 -0.0149 -7 400 420 IIAEGANGPTTPEADKIFL
7 ATP synthase, H+ transporting, mitochondrial F1 gi|32189394 56524.6 40 25.028
complex, beta subunit precursor [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1385.7092 1385.7094 0.0002 0 144 155 IMNVIGEPIDER
1406.681 1406.6974 0.0164 12 226 239 AHGGYSVFAGVGER
1435.7539 1435.7715 0.0176 12 311 324 FTQAGSEVSALLGR
1439.7892 1439.7858 -0.0034 -2 282 294 VALTGLTVAEYFR
1601.8103 1601.8223 0.012 7 265 279 VALVYGQMNEPPGAR
1650.9172 1650.9092 -0.008 -5 95 109 LVLEVAQHLGESTVR
1650.9172 1650.9092 -0.008 -5 95 109 LVLEVAQHLGESTVR
1780.9625 1780.9495 -0.013 -7 144 159 IMNVIGEPIDERGPIK
1815.8694 1815.8885 0.0191 11 407 422 IMDPNIVGSEHYDVAR
1988.0334 1988.0197 -0.0137 -7 388 406 AIAELGIYPAVDPLDSTSR
2023.0105 2023.0178 0.0073 4 463 480 FLSQPFQVAEVFTGHMG
K
2266.0842 2266.0862 0.002 1 325 345 IPSAVGYQPTLATDMGT
MQER
2318.1445 2318.1326 -0.0119 -5 240 259 TREGNDLYHEMIESGVIN
LK
3338.7014 3338.7253 0.0239 7 295 324 DQEGQDVLLFIDNIFRFT
QAGSEVSALLGR
Spot Idx/Pos 188/H4 30 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 Chain A, Structure Of Human Glutamate gi|20151 55973.4 198 100 23 #
Dehydrogenase-Apo Form
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
905.4323 905.4658 0.0335 37 40 46 ESEEQKR
956.52 956.5453 0.0253 26 401 407 LTFKYER
956.52 956.5453 0.0253 26 401 407 LTFKYER
963.5258 963.5499 0.0241 25 475 482 YNLGLDLR
1000.4556 1000.4904 0.0348 35 16 23 MVEGFFDR 6 0
1000.4556 1000.4904 0.0348 35 16 23 MVEGFFDR
1059.533 1059.5614 0.0284 27 392 400 NLNHVSYGR
1394.746 1394.7701 0.0241 17 471 482 TAMKYNLGLDLR
1425.6281 1425.6548 0.0267 19 72 83 DDGSWEVIEGYR
1425.6281 1425.6548 0.0267 19 72 83 DDGSWEVIEGYR 6 0
1491.726 1491.7567 0.0307 21 451 463 DIVHSGLAYTMER
1543.8325 1543.8599 0.0274 18 24 37 GASIVEDKLVEDLR 10 37.458
1543.8325 1543.8599 0.0274 18 24 37 GASIVEDKLVEDLR
1581.7291 1581.7565 0.0274 17 71 83 RDDGSWEVIEGYR
1737.8918 1737.9161 0.0243 14 428 443 HGGTIPIVPTAEFQDR
1737.8918 1737.9161 0.0243 14 428 443 HGGTIPIVPTAEFQDR
1748.89 1748.9139 0.0239 14 250 265 TFVVQGFGNVGLHSMR
1748.89 1748.9139 0.0239 14 250 265 TFVVQGFGNVGLHSMR
1837.0516 1837.0806 0.029 16 55 70 IIKPCNHVLSLSFPIR
1837.0516 1837.0806 0.029 16 55 70 IIKPCNHVLSLSFPIR
1915.9218 1915.9493 0.0275 14 160 178 GFIGPGIDVPAPDMSTGE
R
1920.912 1920.9424 0.0304 16 408 423 DSNYHLLMSVQESLER
1920.912 1920.9424 0.0304 16 408 423 DSNYHLLMSVQESLER
1933.0024 1932.9475 -0.0549 -28 131 147 AGVKINPKNYTDNELEK
1958.0381 1958.0604 0.0223 11 294 310 ELEDFKLQHGSILGFPK
1958.0381 1958.0604 0.0223 11 294 310 ELEDFKLQHGSILGFPK
1993.1527 1993.1589 0.0062 3 55 71 IIKPCNHVLSLSFPIRR
2044.0167 2044.0457 0.029 14 159 178 KGFIGPGIDVPAPDMSTG
ER
2044.0167 2044.0457 0.029 14 159 178 KGFIGPGIDVPAPDMSTG
ER
2049.0068 2049.0439 0.0371 18 408 424 DSNYHLLMSVQESLERK
2164.0703 2164.1028 0.0325 15 444 463 ISGASEKDIVHSGLAYTM
ER
2164.0703 2164.1028 0.0325 15 444 463 ISGASEKDIVHSGLAYTM
ER
2242.1714 2242.2017 0.0303 14 347 367 IIAEGANGPTTPEADKIFL
ER
2242.1714 2242.2017 0.0303 14 347 367 IIAEGANGPTTPEADKIFL
ER
2318.1975 2318.209 0.0115 5 250 269 TFVVQGFGNVGLHSMRY
LHR
2441.3035 2441.3164 0.0129 5 345 367 AKIIAEGANGPTTPEADKI
FLER
2497.2139 2497.2927 0.0788 32 405 424 YERDSNYHLLMSVQESL
ERK
2603.3384 2603.3323 -0.0061 -2 95 118 GGIRYSTDVSVDEVKALA
SLMTYK
2742.4211 2742.4666 0.0455 17 368 391 NIMVIPDLYLNAGGVTVS
YFEWLK
3045.4885 3045.5374 0.0489 16 266 293 YLHRFGAKCIAVGESDGS
IWNPDGIDPK
3782.9363 3782.9573 0.021 6 368 400 NIMVIPDLYLNAGGVTVS
YFEWLKNLNHVSYGR
6 ATP synthase, H+ transporting, mitochondrial F1 gi|32189 56524.6 84 99.997
complex, beta subunit precursor [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1385.7092 1385.7341 0.0249 18 144 155 IMNVIGEPIDER
1406.681 1406.7242 0.0432 31 226 239 AHGGYSVFAGVGER
1435.7539 1435.782 0.0281 20 311 324 FTQAGSEVSALLGR
1439.7892 1439.8136 0.0244 17 282 294 VALTGLTVAEYFR
1601.8103 1601.8384 0.0281 18 265 279 VALVYGQMNEPPGAR
1650.9172 1650.9451 0.0279 17 95 109 LVLEVAQHLGESTVR
1748.8561 1748.9139 0.0578 33 45 62 DYAAQTSPSPKAGAATG
R
1748.8561 1748.9139 0.0578 33 45 62 DYAAQTSPSPKAGAATG
R
1780.9625 1780.9805 0.018 10 144 159 IMNVIGEPIDERGPIK
1815.8694 1815.9052 0.0358 20 407 422 IMDPNIVGSEHYDVAR
1988.0334 1988.0648 0.0314 16 388 406 AIAELGIYPAVDPLDSTSR
2023.0105 2023.0638 0.0533 26 463 480 FLSQPFQVAEVFTGHMG
K
2060.9956 2061.0601 0.0645 31 242 259 EGNDLYHEMIESGVINLK
2164.1145 2164.1028 -0.0117 -5 35 55 AAPTAVHPVRDYAAQTS
PSPK
2164.1145 2164.1028 -0.0117 -5 35 55 AAPTAVHPVRDYAAQTS
PSPK
2228.1128 2228.1885 0.0757 34 407 426 IMDPNIVGSEHYDVARGV
QK
2266.0842 2266.1287 0.0445 20 325 345 IPSAVGYQPTLATDMGT
MQER
2318.1445 2318.209 0.0645 28 240 259 TREGNDLYHEMIESGVIN
LK
2732.6045 2732.5076 -0.0969 -35 19 44 RLTPSASLPPAQLLLRAA
PTAVHPVR
3031.6824 3031.5806 -0.1018 -34 63 91 IVAVIGAVVDVQFDEGLP
PILNALEVQGR
3714.886 3714.8579 -0.0281 -8 352 387 GSITSVQAIYVPADDLTD
PAPATTFAHLDATTVLSR
Spot Idx/Pos 189/H6 31 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 lactate dehydrogenase A [Homo sapiens] gi|5031857 36665.4 150 100 21 97.755
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
833.3748 833.3673 -0.0075 -9 100 106 QQEGESR
913.5829 913.5765 -0.0064 -7 91 99 LVIITAGAR
913.5829 913.5765 -0.0064 -7 91 99 LVIITAGAR 21 97.755
1071.5404 1071.5294 -0.011 -10 170 177 FRYLMGER
1071.5404 1071.5294 -0.011 -10 170 177 FRYLMGER
1134.5636 1134.5571 -0.0065 -6 306 315 VTLTSEEEAR
1167.6666 1167.6621 -0.0045 -4 269 278 RVHPVSTMIK
1167.6666 1167.6621 -0.0045 -4 269 278 RVHPVSTMIK
1191.5786 1191.5812 0.0026 2 158 169 VIGSGCNLDSAR
1494.748 1494.7413 -0.0067 -4 158 171 VIGSGCNLDSARFR
1556.8138 1556.8066 -0.0072 -5 100 112 QQEGESRLNLVQR
1633.7825 1633.7809 -0.0016 -1 60 73 GEMMDLQHGSLFLR
1633.7825 1633.7809 -0.0016 -1 60 73 GEMMDLQHGSLFLR
1644.9835 1644.9662 -0.0173 -11 113 126 NVNIFKFIIPNVVK
1874.9614 1874.9647 0.0033 2 58 73 LKGEMMDLQHGSLFLR
1874.9614 1874.9647 0.0033 2 58 73 LKGEMMDLQHGSLFLR
1906.0392 1906.0281 -0.0111 -6 82 99 DYNVTANSKLVIITAGAR
1910.9606 1910.9519 -0.0087 -5 213 228 TLHPDLGTDKDKEQWK
2074.0815 2074.0828 0.0013 1 6 22 DQLIYNLLKEEQTPQNK
2112.0681 2112.0447 -0.0234 -11 246 265 GYTSWAIGLSVADLAESI
MK
2232.158 2232.1401 -0.0179 -8 285 305 DDVFLSVPCILGQNGISD
LVK
2353.2471 2353.2388 -0.0083 -4 244 265 LKGYTSWAIGLSVADLAE
SIMK
2390.3401 2390.3481 0.008 3 77 99 IVSGKDYNVTANSKLVIIT
AGAR
2863.5273 2863.5417 0.0144 5 279 305 GLYGIKDDVFLSVPCILG
QNGISDLVK
4 heterogeneous nuclear ribonucleoprotein A2/B1 isoform gi|4504447 35983.9 48 89.163
A2 [Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1013.4434 1013.4584 0.015 15 192 201 GGNFGFGDSR
1377.6293 1377.627 -0.0023 -2 202 216 GGGGNFGPGPGSNFR
1377.6293 1377.627 -0.0023 -2 202 216 GGGGNFGPGPGSNFR
1410.6873 1410.6952 0.0079 6 162 173 YHTINGHNAEVR
1798.9221 1798.938 0.0159 9 11 26 LFIGGLSFETTEESLR
1879.9659 1879.9691 0.0032 2 102 117 LFVGGIKEDTEEHHLR
1927.017 1927.0332 0.0162 8 10 26 KLFIGGLSFETTEESLR
2189.9053 2189.9114 0.0061 3 314 338 NMGGPYGGGNYGPGGS
GGSGGYGGR
2189.9053 2189.9114 0.0061 3 314 338 NMGGPYGGGNYGPGGS
GGSGGYGGR
2220.0706 2220.0769 0.0063 3 118 135 DYFEEYGKIDTIEIITDR
2277.155 2277.1479 -0.0071 -3 142 161 GFGFVTFDDHDPVDKIVL
QK
2495.0393 2495.0474 0.0081 3 227 254 GFGDGYNGYGGGPGGG
NFGGSPGYGGGR
32 Phosphodiesterase 6A, cGMP-specific, rod, alpha gi|112180437 99482.8 22 0
[Homo sapiens]
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
929.5665 929.5605 -0.006 -6 32 40 LISDLLGAK
1011.5581 1011.5488 -0.0093 -9 621 629 LHGSSILER
1542.8525 1542.8413 -0.0112 -7 318 330 VIDYILHGKEDIK
1784.9146 1784.9069 -0.0077 -4 751 765 TVLQQNPIPMMDRNK
1784.9146 1784.9069 -0.0077 -4 751 765 TVLQQNPIPMMDRNK
1886.9969 1886.9821 -0.0148 -8 198 213 VDGSHFTKRDEEILLK
2249.1138 2249.0938 -0.02 -9 12 29 FLDSNIGFAKQYYNLHYR
2438.2529 2438.2637 0.0108 4 751 771 TVLQQNPIPMMDRNKAD
ELPK
2806.4246 2806.4207 -0.0039 -1 556 579 ITYHNWRHGFNVGQTMF
SLLVTGK
2934.5195 2934.5176 -0.0019 -1 555 579 KITYHNWRHGFNVGQTM
FSLLVTGK
3682.876 3682.8433 -0.0327 -9 207 236 DEEILLKYLNFANLIMKVY
HLSYLHNCETR
Spot Idx/Pos 190/H8 32 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 lactate dehydrogenase A [Homo sapiens] gi|50318 36665.4 119 100
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
833.4152 833.4354 0.0202 24 223 228 DKEQWK
1011.5656 1011.6007 0.0351 35 270 278 VHPVSTMIK
1264.6782 1264.7018 0.0236 19 233 243 QVVESAYEVIK
1644.9835 1645.0377 0.0542 33 113 126 NVNIFKFIIPNVVK
1657.853 1657.8906 0.0376 23 43 57 DLADELALVDVIEDK
1799.0359 1799.0052 -0.0307 -17 269 284 RVHPVSTMIKGLYGIK
1899.032 1899.064 0.032 17 43 59 DLADELALVDVIEDKLK
1906.0392 1906.1049 0.0657 34 82 99 DYNVTANSKLVIITAGAR
1910.9606 1911.0211 0.0605 32 213 228 TLHPDLGTDKDKEQWK
1933.0682 1933.118 0.0498 26 23 42 ITVVGVGAVGMACAISIL
MK
1944.1204 1944.1799 0.0595 31 133 149 LLIVSNPVDILTYVAWK
2112.0681 2112.1367 0.0686 32 246 265 GYTSWAIGLSVADLAESI
MK
2112.0681 2112.1367 0.0686 32 246 265 GYTSWAIGLSVADLAESI
MK
2353.2471 2353.3394 0.0923 39 244 265 LKGYTSWAIGLSVADLAE
SIMK
2390.3401 2390.4207 0.0806 34 77 99 IVSGKDYNVTANSKLVIIT
AGAR
2495.2961 2495.2114 -0.0847 -34 246 268 GYTSWAIGLSVADLAESI
MKNLR
2863.5273 2863.6221 0.0948 33 279 305 GLYGIKDDVFLSVPCILG
QNGISDLVK
3513.7966 3513.8669 0.0703 20 43 73 DLADELALVDVIEDKLKG
EMMDLQHGSLFLR
3611.7886 3611.8848 0.0962 27 178 212 LGVHPLSCHGWVLGEHG
DSSVPVWSGMNVAGVSL
K
Spot Idx/Pos 191/H10 33 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 118 100
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
994.4774 994.4921 0.0147 15 106 114 GDFCIQVGR
994.4774 994.4921 0.0147 15 221 229 GDFCIQVGR
1149.6415 1149.6565 0.015 13 57 66 DRPFFAGLVK
1149.6415 1149.6565 0.015 13 57 66 DRPFFAGLVK
1181.587 1181.5825 -0.0045 -4 40 49 FMQASEDLLK
1344.7633 1344.7744 0.0111 8 122 133 TFIAIKPDGVQR
1344.7633 1344.7744 0.0111 8 7 18 TFIAIKPDGVQR
1516.8845 1516.8854 0.0009 1 134 146 GLVGEIIKRFEQK
1516.8845 1516.8854 0.0009 1 19 31 GLVGEIIKRFEQK
1785.9163 1785.927 0.0107 6 89 105 VMLGETNPADSKPGTIR
1785.9163 1785.927 0.0107 6 204 220 VMLGETNPADSKPGTIR
2034.0806 2034.0894 0.0088 4 50 66 EHYVDLKDRPFFAGLVK
2034.0806 2034.0894 0.0088 4 50 66 EHYVDLKDRPFFAGLVK
2066.0261 2066.0259 -0.0002 0 40 56 FMQASEDLLKEHYVDLK
2066.0261 2066.0259 -0.0002 0 40 56 FMQASEDLLKEHYVDLK
2116.0718 2116.074 0.0022 1 67 85 YMHSGPVVAMVWEGLN
VVK
2116.0718 2116.074 0.0022 1 67 85 YMHSGPVVAMVWEGLN
VVK
3196.6499 3196.6282 -0.0217 -7 40 66 FMQASEDLLKEHYVDLK
DRPFFAGLVK
11 Chain A, Nucleoside Triphosphate, Nucleoside gi|1421609 17155.9 25 0
Diphosphate Mol_id: 1; Molecule: Nucleoside
Diphosphat
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
994.4774 994.4921 0.0147 15 105 113 GDFCIQVGR
994.4774 994.4921 0.0147 15 105 113 GDFCIQVGR
1344.7633 1344.7744 0.0111 8 6 17 TFIAIKPDGVQR
1344.7633 1344.7744 0.0111 8 6 17 TFIAIKPDGVQR
1516.8845 1516.8854 0.0009 1 18 30 GLVGEIIKRFEQK
1516.8845 1516.8854 0.0009 1 18 30 GLVGEIIKRFEQK
1785.9163 1785.927 0.0107 6 88 104 VMLGETNPADSKPGTIR
1785.9163 1785.927 0.0107 6 88 104 VMLGETNPADSKPGTIR
Spot Idx/Pos 192/H12 34 Instr./Spot Origin ab4700/042810 Process Status Analysis Succeeded
Plate [#] Name [1] 042810 4700 Sample Name Spectra 13
Rank Protein Name Accession No. Protein MW Protein Protein Total Ion Total Ion
Score C. I. % Score C. I. %
1 NME1-NME2 protein [Homo sapiens] gi|66392203 30117.6 135 100 17 86.888
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
911.4733 911.4838 0.0105 12 143 149 FEQKGFR
984.6199 984.6309 0.011 11 19 27 GLVGEIIKR 9 5.908
984.6199 984.6309 0.011 11 134 142 GLVGEIIKR
1149.6415 1149.6497 0.0082 7 57 66 DRPFFAGLVK
1149.6415 1149.6497 0.0082 7 57 66 DRPFFAGLVK
1344.7633 1344.7748 0.0115 9 122 133 TFIAIKPDGVQR
1344.7633 1344.7748 0.0115 9 7 18 TFIAIKPDGVQR 10 31.837
1516.8845 1516.8903 0.0058 4 134 146 GLVGEIIKRFEQK
1516.8845 1516.8903 0.0058 4 19 31 GLVGEIIKRFEQK
1785.9163 1785.9252 0.0089 5 204 220 VMLGETNPADSKPGTIR
1785.9163 1785.9252 0.0089 5 89 105 VMLGETNPADSKPGTIR
2034.0806 2034.0925 0.0119 6 50 66 EHYVDLKDRPFFAGLVK
2034.0806 2034.0925 0.0119 6 50 66 EHYVDLKDRPFFAGLVK
2066.0261 2066.0303 0.0042 2 40 56 FMQASEDLLKEHYVDLK
2116.0718 2116.0618 -0.01 -5 67 85 YMHSGPVVAMVWEGLN
VVK
2116.0718 2116.0618 -0.01 -5 67 85 YMHSGPVVAMVWEGLN
VVK
23 nucleoside diphosphate kinase B gi|924935 2058.1 21 0 10 31.837
Peptide Information
Calc. Mass Obsrv. Mass ± da ± ppm Start End Sequence Ion C. I. % Modification
Seq. Seq. Score
1344.7633 1344.7748 0.0115 9 7 18 TFIAIKPDGVQR
1344.7633 1344.7748 0.0115 9 7 18 TFIAIKPDGVQR 10 31.837
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